TUMOR REGISTRY - kfshrc.edu.sa · commitment to fundamental research in cancer biology and stem...
-
Upload
truongdieu -
Category
Documents
-
view
212 -
download
0
Transcript of TUMOR REGISTRY - kfshrc.edu.sa · commitment to fundamental research in cancer biology and stem...
11
Oncology Centre Research Unit
TUMOR REGISTRY ANNUAL REPORT
2014
2
3
4
55
INTRODUCTION We are pleased to present 2014 Annual Tumor Registry Report for the King Faisal Specialist Hospital & Research Centre’s Oncology Centre in Riyadh. The Cancer Registry maintains a complete database of information on all cancer cases diagnosed and/or treated at KFSH&RC. This report highlights the statistical overview of newly diagnosed cancer cases by site, gender, and AJCC Staging for both analytic and non-analytic cases. During 2014, the Tumor Registry abstracted 2,933 new cancer cases; 2,543 were analytic and 390 were non analytic. The highest incidence of cancer among males by site was Leukemia, Colorectal, and HL and among females was carcinoma of the Breast, Thyroid, and Colorectal. This year’s retrospective outcome study is focused on 1,970 renal cancer cases treated at the Oncology Center since 1975. The Tumor Registry database includes over 80,978 cases and reports to the Saudi Cancer Registry (SCR). Oncology Centre continues to provide most advanced, comprehensive, and multidisciplinary cancer care encompassing state-of-the-art radiation therapy, chemotherapy, hematopoietic stem cell transplantation, palliative and rehabilitation to our patients. Accredited by the World Health Organization (WHO) as a Collaborating Centre for Cancer Prevention and Control, the Oncology Centre continues to be the Center of Excellence in clinical research. Involvement in cutting edge clinical trials allows our physicians and researchers to play a pivotal role in advancing new cancer treatments, offering innovative and most promising treatment options to our patients. We have maintained our international cooperative group affiliations as members of Southwest Oncology Group (SWOG), NRG Oncology, Canadian Blood & Marrow Transplantation Group (CBMTG), Center for International Blood & Marrow Transplant Research (CIBMTR) and European Group for Blood and Marrow Transplantation (EBMT). KFSH&RC has spearheaded the local and regional research consortiums as well, notably, Gulf Oncology Regional Group (GORG) and Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. Oncology Center is committed to serve as the pinnacle of excellence in the region as we move to the new King Abdullah Centre for Oncology and Liver Diseases (KACOLD); an integrated and most modern facility for diagnostic and therapeutic areas of cancers and liver diseases. As strong advocates for a continued commitment to fundamental research in cancer biology and stem cell transplantation, Oncology Centre, actively encourages and promotes translational research to enhance clinical applicability of research findings. Major achievements for the last year include fully operational Intra-Operative Radiation Therapy (IORT), Tomotherapy, Cyberknife and operational Brachytherapy for HDR imaging. Radiation Oncology has also introduced Deep Inspiration Breath Hold (DIBH) cardiac sparing technique to treat left-sided breast cancers and Gold plaque Iodine125 brachytherapy for ophthalmic tumors. Society of Clinical Research Associates (SOCRA) Saudi Arabia chapter continues to meet the educational and certification needs of clinical research professionals of the region. As we look to the future of cancer care in the Kingdom, Oncology Centre will continue to deliver evidence based care centered upon the state-of-the art clinical and translational research as per vision 2030. We are extremely grateful to the dedicated staff of the Tumor Registry for their hard work and commitment throughout the year. Special thanks are due to the superb staff of Medical Records, a key component of the Registry’s continued success. Hats off to our committed physicians, nurses and support staff; it is their dedication and perseverance that is the foundation for our success. This report can also be accessed online via Oncology Centre’s website at http://www.kfshrc.edu.sa. Comments and suggestions are welcome to improve our future reports and can be sent to [email protected].
Fazal Hussain, MD, MPH Naeem Chaudhri, MD Mohammad AlShabanah, MD Research Unit Head, Research Unit Director Oncology Centre Oncology Centre Oncology Centre
66
I. KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE TUMOR REGISTRY The Research Unit encompasses Tumor Registry & Clinical Research sections. The King Faisal Specialist Hospital and Research Centre (KFSH&RC) opened in June 1975 to provide specialized medical treatment to the people of Saudi Arabia and to promote the prevention of disease through research and education. It is a national and international tertiary care hospital for Oncology and the principal center for cancer therapy in Saudi Arabia. The mission of the Tumor Registry, a hospital-wide data system, is to describe the burden of cancer in KFSH&RC by collecting complete and high quality cancer data and compiling timely statistics so that data-driven, evidence-based cancer prevention and control programs can be implemented to reduce cancer morbidity and mortality. The Registry was established to meet one of the requirements for an Approved Cancer Program of the American College of Surgeons (ACoS). The database now includes 80,978 malignant cases seen at KFSH&RC from June 1975 through December 31, 2014, as well as cases seen at the Children’s Cancer Centre since its opening in March 1997. The Registry is primarily staffed with certified tumor registrars who support the database in case ascertainment, abstracting, follow up and statistical analyses. The basic source document is the patient's medical record from which pertinent information is abstracted for use in the Registry. The electronic data system used was the Cansur 3.0 designed by the ACoS, for cases seen from 1975 to 2007. Starting with 2008 cases, the software being used is CNExT, developed by C/NET Solutions which is part of the U.S. Public Health Institute. The data maintained in the Tumor Registry provides the statistics for the publication of the KFSH&RC Annual Report which summarizes the hospital's cancer experience. The data also supports a wide variety of reports at the request of physicians, researchers and ancillary personnel. These reports support patient management and outcome, basic and clinical research investigations, educational publications and presentations, and resource utilization. In 2014, the Tumor Registry supported myriad of data requests (see Appendix for a listing of requests for Tumor Registry data). It also identified and reported to the Saudi Cancer Registry 2,933 new cases seen in 2014.
77
II. ACKNOWLEDGEMENTS The cancer program is a combined effort of the extraordinary team of professionals at the King Faisal Specialist Hospital and Research Centre. It is not possible to enumerate all those involved in providing hope and healing to cancer patients and their families. The Tumor Registry staff greatly appreciates the tireless efforts of all the caring professionals from all disciplines for their dedication, commitment and collaboration to ensure highest standards in community outreach, clinical trials, staff education, patient care improvement, outcome analysis and tumor registry quality. The clinical expertise and proficiency demonstrated by our team, coupled with an incredible dedication to patient care and service excellence, allows the Oncology Centre to achieve remarkable outcomes and to consistently exceed the needs and expectations of patients and their families. The information in this report includes cancer incidence, site, and extent of disease at diagnosis, treatment, cancer trends, and outcomes to better understand the changing patterns of cancer. The following departments have assisted throughout the year and without their support this report would not have been possible. The Tumor Registry staff takes pride in acknowledging these departments:
Department of Pathology and Laboratory Medicine Medical Records Services Information Technology Affairs Department of Pediatric Hematology/Oncology Central Data Unit, Dept. of Ped Hem/Onc Saudi Cancer Registry Home Health Care Oncology Centre
88
III. KFSH&RC CANCER PATIENT POPULATION A total of 2,933 cases were accessioned in 2014, with 1,318 males and 1,614 females or a male/female ratio of 0.8:1.
FIGURE 1
DISTRIBUTION OF CASES ACCESSIONED BY YEAR 1975 – 2014 (TOTAL CASES = 80,978)
From the opening of the hospital (mid 1975) until December 2014, 80,978 cancer cases were registered (40,431 males and 40,546 females) with a male/female ratio of 0.9:1. There were 10,373 (12.8%) pediatric cases (0 to 14 years of age) and 70,605 (87.2%) adults (15 years old and above). In 2014, the proportions were 8.8% (259) for pediatrics and 91.2% (2,674) for adults.
8
III. KFSH&RC CANCER PATIENT POPULATION A total of 2,933 cases were accessioned in 2014, with 1,318 males and 1,614 females or a male/female ratio of 0.8:1.
FIGURE 1
DISTRIBUTION OF CASES ACCESSIONED BY YEAR 1975 – 2014 (TOTAL CASES = 80,978)
From the opening of the hospital (mid 1975) until December 2014, 80,978 cancer cases were registered (40,431 males and 40,546 females) with a male/female ratio of 0.9:1. There were 10,373 (12.8%) pediatric cases (0 to 14 years of age) and 70,605 (87.2%) adults (15 years old and above). In 2014, the proportions were 8.8% (259) for pediatrics and 91.2% (2,674) for adults.
FIGURE 1
DISTRIBUTION OF CASES ACCESSIONED BY YEAR1975-2014 (TOTAL CASES = 80,978)
NU
MBE
R O
F CA
SES
YEAR
3,000
2,500
2,000
1,500
1,000
500
00
500
1000
1500
2000
2500
3000
1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
NUMBE
ROFCA
SES
YEAR
FIGURE1
DISTRIBUTIONOFCASESACCESSIONEDBYYEAR1975-2014(TOTALCASES=80,978)
FEMALE
MALE
9
TABLE 1 CASES SEEN AT KFSH&RC (MALE/FEMALE & PEDIATRICS/ADULTS) BY 5-YEAR
PERIOD
1975 – 2014
Saudi nationals totaled 2,826 (96.4%) in 2014 and the non-Saudi, 107 (3.6%). During the period 1975 to 2014, the former accounted for 89.4% (72,416) while the latter, 10.6% (8,562).
FIGURE 2
DISTRIBUTION OF CASES BY NATIONALITY1975 - 2014 (TOTAL CASES = 80,978)
FIGURE2
DISTRIBUTIONOFCASESBYNATIONALITY1975-2014(TOTALCASES=80,978)
SAUDI72,416(89.4%)
NON-SAUDI8562(10.6%)YEMENI2,304(2.8%)LEB,SYR,PAL,JORD1,820(2.2%)AFRICAN1,124(1.4%)EGYPTIAN989(1.2%)GCC844(1.0%)ALLOTHERS1,481(1.8%)
2014 (TOTAL CASES = 2,933)
NON-SAUDI 8562 (10.6%)
YEMENI 2,304 (2.8%)LEB,SYR,PAL,JORD 1,820 (2.2%)AFRICAN 1,124 (1.4%)EGYPTIAN 989 (1.2%)GCC 844 (1.0%)ALL OTHERS 1,481 (1.8%)
NON-SAUDI 107 (3.6%)
YEMENI 16 (0.5%)GCC 6 (0.2%)LEB,SYR,PAL,JORD 13 (0.5%)AFRICAN 6 (0.2%)EGYPTIAN 22 (0.8%)ALL OTHERS 44 (1.5%)
SAUDI 72,416 (89.4%)
SAUDI 2,826 (96.4%)
2014(TOTALCASES=2,933)
SAUDI2,826(96.4%) NON-SAUDI107(3.6%)
YEMENI16(0.5%)GCC6(0.2%)LEB,SYR,PAL,JORD13(0.5%)AFRICAN6(0.2%)EGYPTIAN22(0.8%)ALLOTHERS44(1.5%)
TABLE 1
CASES SEEN AT KFSH&RC (MALE/FEMALE & PEDIATRICS/ADULTS) BY 5-YEAR PERIOD1975 - 2014
1975-1976* 1977-1981 1982-1986 1987-1991 1992-1996 1997-2001 2002 - 2006 2007-2011 2012-2014 TOTAL
MALE 280 2,980 4,150 4,969 5,562 6,427 6,529 5,819 3,715 40,431FEMALE 135 1,945 3,358 4,341 5,347 6,753 7,199 6,952 4,516 40,546
TOTAL 415 4,925 7,508 9,310 10,909 13,180 13,728 12,771 8,231 80,977
M/F RATIO 2.1:1 1.5:1 1.2:1 1.1:1 1.0:1 1.0:1 0.9:1 0.8:1 0.8:1 0.9:1
PEDIATRICS** 55 593 985 1164 1397 1892 1893 1566 828 10,373(%) 13.3% 12.0% 13.1% 12.5% 12.8% 14.4% 13.8% 12.3% 10.1% 12.8%
ADULTS 360 4,332 6,523 8,146 9,512 11,288 11,835 11,205 7,404 70,605(%) 86.7% 88.0% 86.9% 87.5% 87.2% 85.6% 86.2% 87.7% 89.9% 87.2%
TOTAL 415 4,925 7,508 9,310 10,909 13,180 13,728 12,771 8,232 80,978
* First two years of KFSH&RC partial operation.** Pediatrics = 0 to 14 years of age; Adults = 15 years and above.
*** One Pediatric Transgender Case was excluded from any specific classification analysis on the basis of gender.
TABLE 1
CASES SEEN AT KFSH&RC (MALE/FEMALE & PEDIATRICS/ADULTS) BY 5-YEAR PERIOD1975 - 2014
1975-1976* 1977-1981 1982-1986 1987-1991 1992-1996 1997-2001 2002 - 2006 2007-2011 2012-2014 TOTAL
MALE 280 2,980 4,150 4,969 5,562 6,427 6,529 5,819 3,715 40,431FEMALE 135 1,945 3,358 4,341 5,347 6,753 7,199 6,952 4,516 40,546
TOTAL 415 4,925 7,508 9,310 10,909 13,180 13,728 12,771 8,231 80,977
M/F RATIO 2.1:1 1.5:1 1.2:1 1.1:1 1.0:1 1.0:1 0.9:1 0.8:1 0.8:1 0.9:1
PEDIATRICS** 55 593 985 1164 1397 1892 1893 1566 828 10,373(%) 13.3% 12.0% 13.1% 12.5% 12.8% 14.4% 13.8% 12.3% 10.1% 12.8%
ADULTS 360 4,332 6,523 8,146 9,512 11,288 11,835 11,205 7,404 70,605(%) 86.7% 88.0% 86.9% 87.5% 87.2% 85.6% 86.2% 87.7% 89.9% 87.2%
TOTAL 415 4,925 7,508 9,310 10,909 13,180 13,728 12,771 8,232 80,978
* First two years of KFSH&RC partial operation.** Pediatrics = 0 to 14 years of age; Adults = 15 years and above.
*** One Pediatric Transgender Case was excluded from any specific classification analysis on the basis of gender.
1010
Geographically, the referral pattern in 2014 was mainly from the Riyadh region with 42.2% of all cases, followed by the Asir region and the Eastern Province with 10.3% and 8%, respectively. During the 39 years in review, 35.9% were referred from Riyadh, 14.3% from the Eastern Province and 10.7% from Mekkah. These percentages reflect the KFSH&RC actual experience rather than adjusted to reflect the population of those regions.
1111
TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC The crude relative frequency is the proportion of a given cancer in relation to all cases in a clinical or pathological series. Although such frequencies are subject to many biases, historically many elevated frequencies have been confirmed when complete cancer registration was introduced. Acceptance of cases to KFSH&RC is based on eligibility criteria, considering the nature of disease and availability of services. Breast cancer led the list of total cancer cases seen from 1975 to 2014 with 12%, followed by leukemia (8.6%), non-hodgkin’s lymphoma (7.4%), thyroid (7%) and colon, rectum (5.3%).
FIGURE 4
DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES 1975 – 2014 (TOTAL CASES = 80,978*)
*One Pediatric Transgender Case was excluded from any specific classification analysis on the basis of gender.
11
TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC The crude relative frequency is the proportion of a given cancer in relation to all cases in a clinical or pathological series. Although such frequencies are subject to many biases, historically many elevated frequencies have been confirmed when complete cancer registration was introduced. Acceptance of cases to KFSH&RC is based on eligibility criteria, considering the nature of disease and availability of services. Breast cancer led the list of total cancer cases seen from 1975 to 2014 with 12%, followed by leukemia (8.6%), non-hodgkin’s lymphoma (7.4%), thyroid (7%) and colon, rectum (5.3%).
FIGURE 4
DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES 1975 – 2014 (TOTAL CASES = 80,978*)
*One Pediatric Transgender Case was excluded from any specific classification analysis on the basis of gender.
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
NUMBE
ROFCA
SES
FIGURE4DISTRIBUTIONOF20MOSTCOMMONMALIGNANCIES
1975-2014(TOTALCASES=80,978)
FEMALE
MALE
MALIGNANCIES
BREAST
LEUKEMIA NHL
THYROID
COLON, RECTUM
BRAIN, CNS
ORAL CAVITY
HODGKIN’S LYMPHOMA
LUNG, BRONCHUSLIVER
NASOPHARYNX
BLADDER
SOFT TISSUE
STOMACH
ESOPHAGUS
KIDNEY, URINARYBONE
OTHER SKIN CANCEROVARY
CERVIX UTERI
10,000
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
NU
MBE
R O
F CA
SES
MALIGNANCIES
FIGURE 4
DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES 1975 - 2014 (TOTAL CASES = 80,978)
12
0
500
1000
1500
2000
2500
3000
3500
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROFCA
SES
AGEINYEARS
BREASTCANCERCASES
REGIONAL4,842(49.7%)
LOCALIZED2,254(22.6%)
UNSTAGEABLE649(6.7%)
DISTANT1,727(17.7%)
INSITU272(2.5%)
BREAST CANCER CASESN
UM
BER
OF
CA
SES
AGE IN YEARS
3,000
3,500
2,500
2,000
1,500
1,000
500
000-09
00-09
10-19
10-19
20-29
20-29
30-39
30-39
40-49
40-49
50-59
50-59
60-69
60-69
70-79
70-79
80-89
80-89
90+
90+
0
500
1000
1500
2000
2500
3000
3500
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROFCA
SES
AGEINYEARS
BREASTCANCERCASES
REGIONAL4,842(49.7%)
LOCALIZED2,254(22.6%)
UNSTAGEABLE649(6.7%)
DISTANT1,727(17.7%)
INSITU272(2.5%)
FIGURE 5
DISTRIBUTION OF FIVE MOST COMMON MALIGNANCIESBY AGE AT DIAGNOSIS AND SEER SUMMARY STAGE
(1975 - 2014)
IN SITU 272 (2.5%)
REGIONAL 4,842 (49.7%) UNSTAGEABLE 649 (6.7%)
DISTANT 1,727 ( 17.7 %)
LOCALIZED 2,254 (22.6%)
0
500
1000
1500
2000
2500
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROFCA
SES
AGEINYEARS
LEUKEMIACASES1975-2014
NU
MB
ER O
F C
ASE
S
LEUKEMIA CASES 1975-2014
AGE IN YEARS
2,500
2,000
1,500
1,000
500
0
13
0
200
400
600
800
1000
1200
1400
1600
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBER
OFCA
SES
AGEINYEARS
THYROIDCANCERCASES
[CATEGORYNAME][VALUE]([PERCENTAGE])
LOCALIZED2,440(43%)
REGIONAL2244(39%)
UNSTAGEABLE508(9%)
DISTANT497(9%)
0
200
400
600
800
1000
1200
1400
1600
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROFC
ASES
AGEINYEARS
THYROIDCANCERCASES
[CATEGORYNAME][VALUE]([PERCENTAGE])
LOCALIZED2,440(43%)
REGIONAL2244(39%)
UNSTAGEABLE508(9%)
DISTANT497(9%)
00-09
00-09
10-19
10-19
20-29
20-29
30-39
30-39
40-49
40-49
50-59
50-59
60-69
60-69
70-79
70-79
80-89
80-89
90+
90+
0
100
200
300
400
500
600
700
800
900
1000
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROF
CASES
AGEINYEARS
NON-HODGKIN'SLYMPHOMACASES
DISTANT3,041(51%)
LOCALIZED927(15.6%)
REGIONAL1,659(27.8%)
UNSTAGEABLE330(5.5%)
0
100
200
300
400
500
600
700
800
900
1000
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROFCA
SES
AGEINYEARS
NON-HODGKIN'SLYMPHOMACASES
DISTANT3,041(51%)
LOCALIZED927(15.6%)
REGIONAL1,659(27.8%)
UNSTAGEABLE330(5.5%)
NU
MB
ER O
F C
ASE
S
AGE IN YEARS
NON-HODGKIN’S LYMPHOMA CASES
0
100
200
300
400
500
600
700
800
900
1000
NU
MB
ER O
F C
ASE
S
AGE IN YEARS
THYROID CANCER CASES
LOCALIZED 927 (15.6%)
REGIONAL 1,659 (27.8%)
UNSTAGEABLE 330 (5.5%)DISTANT 3,041 (51%)
REGIONAL 2244 (39%)
DISTANT 497 (9%)
UNSTAGEABLE 508 (9%)
LOCALIZED 2,440 (43%)
1,400
1,600
1,200
1,000
800
600
400
200
0
14
0
200
400
600
800
1000
1200
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
NUMBE
ROF
CAS
ES
AGEINYEARS
COLON,RECTUMCANCERCASES
REGIONAL1,938(46%)
LOCALIZED512(12.0%)
UNSTAGEABLE456(11%)
INSITU17(0.4%)
COLON, RECTUM CANCER CASES
NU
MB
ER O
F C
ASE
S
AGE IN YEARS
0
200
400
600
800
1000
1200
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
REGIONAL 1,938 (46%)
LOCALIZED 512(12.0 %)
UNSTAGEABLE 456 (11%)
IN SITU 17 (0.4%)
DISTANT 1341 (31.0%)
1515
TABLE 2 TEN MOST COMMON MALIGNANCIES BY AGE GROUP AT DIAGNOSIS
1975-2014
SITE AGE GROUP No % SITE AGE GROUP No %
BREAST 00 - 14 2 0.0 BRAIN, CNS 00 - 14 1,697 45.6
15 - 39 2,918 29.9 15 - 39 1,002 27.0
40 - 60 5,493 56.4 40 - 60 701 18.9
>60 1,331 13.7 >60 317 8.5
SITE AGE GROUP No % SITE AGE GROUP No %
LEUKEMIA 00 - 14 3,063 44.2 ORAL CAVITY 00 - 14 45 1.2
15 - 39 2,383 34.4 15 - 39 511 14.2
40 - 60 1,103 15.9 40 - 60 1,485 41.2
>60 380 5.5 >60 1,567 43.4
SITE AGE GROUP No % SITE AGE GROUP No %
NON-HODGKIN'S 00 - 14 871 14.6 HODGKIN'S 00 - 14 941 28.8
LYMPHOMA 15 - 39 1,601 26.9 LYMPHOMA 15 - 39 1,763 53.8
40 - 60 1,914 32.1 40 - 60 428 13.1
>60 1,571 26.4 >60 141 4.3
SITE AGE GROUP No % SITE AGE GROUP No %
THYROID 00 - 14 109 1.9 LUNG 00 - 14 12 0.4
15 - 39 2,833 49.8 15 - 39 179 6.1
40 - 60 1,986 34.9 40 - 60 1,281 44.0
>60 762 13.4 >60 1,440 49.5
SITE AGE GROUP No % SITE AGE GROUP No %
COLON, RECTUM 00 - 14 14 0.3 LIVER 00 - 14 105 3.8
15 - 39 735 17.2 15 - 39 153 5.5
40 - 60 2,078 48.7 40 - 60 179 42.4
>60 1,437 33.8 >60 1,342 48.3
SITE AGE GROUP No % SITE AGE GROUP No %
BREAST 00 - 14 2 0.0 BRAIN, CNS 00 - 14 1,697 45.6
15 - 39 2,918 29.9 15 - 39 1,002 27.0
40 - 60 5,493 56.4 40 - 60 701 18.9
>60 1,331 13.7 >60 317 8.5
SITE AGE GROUP No % SITE AGE GROUP No %
LEUKEMIA 00 - 14 3,063 44.2 ORAL CAVITY 00 - 14 45 1.2
15 - 39 2,383 34.4 15 - 39 511 14.2
40 - 60 1,103 15.9 40 - 60 1,485 41.2
>60 380 5.5 >60 1,567 43.4
SITE AGE GROUP No % SITE AGE GROUP No %
NON-HODGKIN'S 00 - 14 871 14.6 HODGKIN'S 00 - 14 941 28.8
LYMPHOMA 15 - 39 1,601 26.9 LYMPHOMA 15 - 39 1,763 53.8
40 - 60 1,914 32.1 40 - 60 428 13.1
>60 1,571 26.4 >60 141 4.3
SITE AGE GROUP No % SITE AGE GROUP No %
THYROID 00 - 14 109 1.9 LUNG 00 - 14 12 0.4
15 - 39 2,833 49.8 15 - 39 179 6.1
40 - 60 1,986 34.9 40 - 60 1,281 44.0
>60 762 13.4 >60 1,440 49.5
SITE AGE GROUP No % SITE AGE GROUP No %
COLON, RECTUM 00 - 14 14 0.3 LIVER 00 - 14 105 3.8
15 - 39 735 17.2 15 - 39 153 5.5
40 - 60 2,078 48.7 40 - 60 179 42.4
>60 1,437 33.8 >60 1,342 48.3
16
0
500
1000
1500
2000
2500
NUMBE
ROFCA
SES
FIGURE7DISTRIBUTIONOF10MOSTCOMMONPEDIATRICMALIGNANCIESBYHISTOLOGY
1975-2014(TOTALCASES=10,372)
FEMALE
MALE
MALIGNANCIES
0
500
1000
1500
2000
2500
3000
3500
NUMBE
ROFCA
SES
FIGURE6DISTRIBUTIONOF10MOSTCOMMONPEDIATRICMALIGNANCIES
1975-2014(TOTALCASES=10,372)
FEMALE
MALE
MALIGNANCIES
16
Cancer among pediatrics (under the age of 15) accounted for 12.8% of all cases from 1975 to 2014. The five most common pediatric malignancies were leukemia (29.6%), brain/CNS (16.4%), hodgkin’s lymphoma (9.1%), non-hodgkin’s lymphoma (8.4%) and bone (6.9%).
FIGURE 6
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES 1974 - 2014 (TOTAL CASES = 10,372)
FIGURE 7
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY 1975 - 2014 (TOTAL CASES = 10,372)
FIGURE 6
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES1975 - 2014 (TOTAL CASES = 10,372)
FIGURE 7
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY1975 - 2014 (TOTAL CASES = 10,372)
NU
MB
ER O
F C
ASE
S
MALIGNANCIES
MALIGNANCIES
NU
MB
ER O
F C
ASE
S
LEUKEMIA
ACUTE LYMPHOID LEUKEMIA
HODGKIN’S LYMPHOMA
NON-HODGKIN’S LYMPHOMA
ACUTE MYELOID LEUKEMIA
RETINOBLASTOMA
NEUROBLASTOMA
ASTROCYTOMA
MEDULLOBLASTOMA
NEPHROBLASTOMA
OSTEOSARCOMA
BRAIN, CNS
HODGKIN’S LYMPHOMA
NON-HODGKIN’S LYMPHOMABONE
SOFT TISSUE EYE
KIDNEY, URINARY
OTHER ENDOCRINE
THYROID
3,000
3,500
2,500
1,500
1,000
500
0
2,500
2,000
1,500
1,000
500
0
2,000
17
18
19
Site
Gro
up
197
7-19
81
199
7-20
01
200
2-20
06
200
7-20
11No
%
No%
No%
No%
No%
No%
No%
No%
No%
No%
Oral
Cavit
y15
3.6
310
6.3
436
5.8
535
5.7
534
4.9
520
3.9
521
3.8
505
4.0
288
3.3
3,66
44.
5Na
soph
aryn
x14
3.4
192
3.9
250
3.3
329
3.5
319
2.9
502
3.8
427
3.1
351
2.7
189
2.3
2,57
33.
2Es
opha
gus
163.
930
46.
234
24.
634
83.
726
82.
523
61.
819
91.
515
11.
281
1.2
1,94
52.
4St
omac
h17
4.1
204
4.1
288
3.8
249
2.7
276
2.5
234
1.8
294
2.1
276
2.2
197
2.3
2,03
52.
5Sm
all In
testi
ne0
0.0
100.
214
0.2
130.
125
0.2
320.
227
0.2
270.
239
0.3
187
0.2
Colon
112.
770
1.4
961.
316
41.
816
21.
528
42.
244
73.
345
43.
634
93.
92,
037
2.5
Rectu
m &
Rec
tosig
moid
30.
780
1.6
108
1.4
166
1.8
248
2.3
367
2.8
523
3.8
442
3.5
290
3.8
2,22
72.
8An
us, A
nal C
anal,
Ano
rectu
m0
0.0
160.
333
0.4
270.
340
0.4
310.
235
0.3
170.
115
0.1
214
0.3
Liver
225.
320
04.
131
24.
233
83.
646
64.
344
53.
430
82.
241
33.
227
53.
82,
779
3.4
Gallb
ladde
r2
0.5
150.
327
0.4
460.
573
0.7
620.
557
0.4
470.
438
0.2
367
0.5
Bile
Ducts
20.
59
0.2
180.
220
0.2
280.
343
0.3
350.
351
0.4
310.
423
70.
3Pa
nccr
eas
61.
467
1.4
100
1.3
880.
911
61.
114
01.
116
31.
216
51.
316
65.
310
111.
2Re
trope
riton
eum
, Per
itone
um0
0.0
60.
14
0.1
30.
04
0.0
60.
011
0.1
110.
118
0.2
630.
1Ot
her D
igesti
ve0
0.0
130.
36
0.1
160.
29
0.1
20.
09
0.1
80.
10
0.0
630.
1Na
sal C
avity
, Sinu
s, Ea
r4
1.0
370.
837
0.5
620.
747
0.4
450.
354
0.4
370.
315
0.3
338
0.4
Lary
nx6
1.4
701.
499
1.3
137
1.5
166
1.5
161
1.2
176
1.3
116
0.9
580.
798
91.
2Lu
ng /
Bron
chus
143.
419
84.
038
25.
143
84.
742
43.
947
33.
641
93.
132
02.
523
02.
82,
898
3.6
Pleu
ra0
0.0
10.
03
0.0
50.
113
0.1
150.
112
0.1
100.
16
0.1
650.
1Ot
her R
espir
ator
y & T
hora
cic0
0.0
60.
16
0.1
170.
226
0.2
270.
217
0.1
250.
212
0.2
136
0.2
Leuk
emia
358.
442
18.
564
98.
678
78.
588
18.
11,
219
9.2
1,17
48.
61,
074
8.4
691
9.8
6,93
18.
6M
yelom
a6
1.4
450.
970
0.9
127
1.4
142
1.3
101
0.8
107
0.8
151
1.2
700.
681
91.
0Ot
her H
emat
opoie
tic1
0.2
70.
117
0.2
120.
17
0.1
280.
240
0.3
930.
786
1.2
291
0.4
Bone
71.
710
02.
016
32.
219
72.
127
42.
535
42.
733
92.
530
22.
416
62.
11,
902
2.3
Soft
tissu
e17
4.1
141
2.9
192
2.6
276
3.0
304
2.8
370
2.8
340
2.5
329
2.6
206
2.8
2,17
52.
7M
elano
ma
of sk
in4
1.0
330.
742
0.6
430.
547
0.4
260.
232
0.2
310.
215
0.3
273
0.3
Kapo
si's S
arco
ma
10.
213
0.3
250.
328
0.3
360.
333
0.3
410.
336
0.3
200.
123
30.
3Ot
her S
kin C
ance
r15
3.6
182
3.7
279
3.7
227
2.4
260
2.4
259
2.0
261
1.9
191
1.5
122
1.3
1,79
62.
2Br
east
276.
532
26.
563
38.
484
29.
01,
193
10.9
1,71
413
.01,
920
14.0
1,82
514
.312
6814
.39,
744
12.0
Cerv
ix Ut
eri
102.
410
52.
118
72.
521
32.
325
12.
327
52.
123
81.
719
31.
511
81.
51,
590
2.0
Corp
us U
teri
20.
525
0.5
530.
789
1.0
114
1.0
156
1.2
275
2.0
335
2.6
218
2.7
1,26
71.
6Ov
ary
81.
978
1.6
150
2.1
222
2.4
259
2.4
280
2.1
252
1.8
267
2.1
149
1.7
1,66
52.
1Va
gina
00.
010
0.2
80.
111
0.1
140.
16
0.0
50.
04
0.0
10.
059
0.1
Vulva
00.
04
0.1
160.
213
0.1
170.
27
0.1
90.
116
0.1
80.
290
0.1
Othe
r Fem
ale G
enita
l1
0.2
270.
548
0.6
650.
761
0.6
300.
262
0.5
310.
28
0.1
333
0.4
Pros
tate
71.
735
0.7
101
1.3
116
1.2
199
1.8
246
1.9
288
2.1
228
1.8
143
1.4
1,36
31.
7Te
stis
30.
753
1.1
580.
871
0.8
950.
990
0.7
950.
711
90.
974
0.5
658
0.8
Penis
10.
24
0.1
90.
111
0.1
50.
05
0.0
40.
01
0.0
20.
142
0.1
Othe
r Male
Gen
ital
00.
03
0.1
40.
15
0.1
20.
02
0.0
80.
11
0.0
10.
026
0.0
Blad
der
112.
714
12.
919
62.
633
03.
534
13.
140
23.
142
03.
134
72.
721
02.
32,
398
3.0
Kidn
ey &
Ren
al Pe
lvis
92.
287
1.8
138
1.8
188
2.0
263
2.4
306
2.3
317
2.3
409
3.2
253
3.1
1,97
02.
4Ur
eter
00.
00
0.0
20.
06
0.1
50.
09
0.1
70.
17
0.1
00.
036
0.0
Othe
r Urin
ary
00.
00
0.0
20.
02
0.0
10.
03
0.0
30.
00
0.0
180.
129
0.0
Eye
61.
495
1.9
130
1.7
144
1.5
118
1.1
114
0.9
890.
610
30.
872
1.0
871
1.1
Brain
, CNS
276.
515
53.
130
94.
144
34.
757
35.
374
05.
672
45.
247
53.
727
33.
73,
719
4.6
Thyr
oid10
2.4
179
3.6
333
4.4
545
5.9
730
6.7
938
7.1
1,01
97.
41,
165
77
19.
45,
690
7.0
Othe
r End
ocrin
e2
0.5
270.
561
0.8
430.
572
0.7
840.
613
21.
011
40.
954
0.9
589
0.7
Hodg
kin's
Lym
phom
a32
7.7
206
4.2
240
3.2
311
3.3
390
3.6
542
4.1
628
4.6
558
4.4
367
4.5
3,27
44.
0No
n-Ho
dgkin
's Ly
mph
oma
276.
549
110
.069
39.
275
28.
177
97.
198
77.
595
87.
081
06.
445
95.
85,
956
7.4
Unkn
own
or Ill
-Def
ined
143.
412
82.
613
91.
919
02.
023
22.
122
91.
720
71.
513
01.
092
0.9
1,36
11.
7
TOTA
L41
510
0.04,9
2510
0.07,5
0810
0.09,3
1010
0.010
,909
100.0
13,18
010
0.013
,728
100.0
12,77
110
0.08,2
3210
0.080
,978
100.0
1975
-197
6TO
TAL
2012
-201
419
92-1
996
1987
-199
119
82-1
986
20
0
5
10
15
20
25
30
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
NUMBE
ROFCA
SES
AGEINYEARS
FIGURE9DISTRIBUTIONOFPEDIATRICCASESBYAGEATDIAGNOSIS
2014(TOTALCASES=259)
FEMALE
MALE
0
50
100
150
200
250
300
350
00-04 05-09
10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
NUMBE
ROFCA
SES
AGEINYEARS
FIGURE8AGEDISTRIBUTIONOFALLCASESBYAGEATDIAGNOSIS
2014(TOTALCASES=2933)
FEMALE
MALE
20
The largest number of cases in 2014 was noted in the 5th and 6th decades of life in males and in the 4th and 5th in females. The mean age was 45.8, median age was 48, and the mode was 50 years of age. Pediatric malignancies were most common among children at less than two years of age.
FIGURE 8
DISTRIBUTION OF 20 ALL CASES BY AGE AT DIAGNOSIS 2014 (TOTAL CASES = 2,543)
FIGURE 9
DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS 2014 (TOTAL CASES = 259)
Of the 2,933 cases in 2014, 2,543 (86.7%) were analytic (defined as cases which were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC). The remaining 390 cases (13.3%) were non-analytic (defined as cases diagnosed elsewhere and received all of their first course of treatment elsewhere). Out of the 2,543 analytic cases, pediatric cases totaled 219. See Table 5 for the distribution of cases by site, sex, class of case, and stage at diagnosis and Tables 6, 7 and 8 for the distributions of analytic cases by site, sex and age at diagnosis. 20
The largest number of cases in 2014 was noted in the 5th and 6th decades of life in males and in the 4th and 5th in females. The mean age was 45.8, median age was 48, and the mode was 50 years of age. Pediatric malignancies were most common among children at less than two years of age.
FIGURE 8
DISTRIBUTION OF 20 ALL CASES BY AGE AT DIAGNOSIS 2014 (TOTAL CASES = 2,543)
FIGURE 9
DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS 2014 (TOTAL CASES = 259)
Of the 2,933 cases in 2014, 2,543 (86.7%) were analytic (defined as cases which were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC). The remaining 390 cases (13.3%) were non-analytic (defined as cases diagnosed elsewhere and received all of their first course of treatment elsewhere). Out of the 2,543 analytic cases, pediatric cases totaled 219. See Table 5 for the distribution of cases by site, sex, class of case, and stage at diagnosis and Tables 6, 7 and 8 for the distributions of analytic cases by site, sex and age at diagnosis.
FIGURE 8
AGE DISTRIBUTION OF ALL CASES BY AGE AT DIAGNOSIS2014 (TOTAL CASES = 2933)
FIGURE 9
DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS2014 (TOTAL CASES = 259)
AGE IN YEARS
AGE IN YEARS
250
350
300
200
150
100
50
0
30
25
20
15
10
5
0<1
00-04 05-09 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
1 2 3 4 5 6 7 8 9 10 11 12 13 14
NU
MB
ER O
F C
ASE
SN
UM
BER
OF
CA
SES
21
A N
A L
Y T
I C
C A
S E
SM
AJ
OR
SIT
E G
RO
UP
ST
O T
A L
G E
N D
E R
CL
AS
S O
F C
AS
ES
E E
RG
E N
E R
A L
S U
M M
A R
YS
T A
G E
Nu
mb
er
%M
ale
Fe
ma
leA
na
lyti
cN
on
-An
aly
tic
In S
itu
Lo
ca
lize
dR
eg
ion
al
Dis
tan
tU
ns
tag
ea
ble
Ora
l C
avity
11
33
.96
44
91
01
12
13
94
41
60
Na
so
ph
ary
nx
59
2.0
43
16
58
10
53
32
00
Eso
ph
ag
us
30
1.0
21
92
73
06
14
61
Sto
ma
ch
74
2.5
36
38
60
14
08
23
27
2S
ma
ll I
nte
stin
e2
00
.71
46
14
60
26
60
Co
lon
13
04
.46
46
61
03
27
01
34
74
20
Re
ctu
m &
Re
cto
sig
mo
id1
00
3.4
64
36
83
17
08
48
27
0A
nu
s,
An
al
Ca
na
l, A
no
rectu
m7
0.2
25
61
11
31
0L
ive
r8
02
.74
43
67
55
04
51
61
31
Ga
llbla
dd
er
22
0.8
71
51
84
04
59
0B
ile D
ucts
12
0.4
11
11
11
03
62
0P
an
cre
as
59
2.0
37
22
49
10
08
15
26
0R
etr
op
erito
ne
um
, P
erito
ne
um
50
.23
24
10
04
00
Na
sa
l C
avity,
Sin
us,
Ea
r4
0.1
22
40
00
31
0L
ary
nx
18
0.6
18
01
62
01
03
21
Lu
ng
/ B
ron
ch
us
77
2.6
70
21
67
10
01
31
24
11
Oth
er
Re
sp
ira
tory
& T
ho
racic
20
.12
02
00
20
00
Le
uke
mia
20
97
.11
27
83
17
23
70
00
17
20
Mye
lom
a2
60
.92
06
21
50
00
21
0O
the
r H
em
ato
po
ietic
29
1.0
16
02
72
00
02
70
Bo
ne
63
2.1
34
29
56
70
26
16
13
1S
oft
Tis
su
e6
12
.13
82
34
41
70
16
16
12
0M
ela
no
ma
of
Skin
40
.12
23
10
10
20
Ka
po
si's
Sa
rco
ma
12
0.4
10
21
11
06
32
0O
the
r S
kin
Ca
nce
r4
51
.52
61
94
05
13
04
41
Bre
ast
46
61
5.9
14
65
43
72
92
31
19
20
58
37
Ce
rvix
Ute
ri4
31
.50
43
38
56
41
97
0C
orp
us
Ute
ri8
52
.90
85
85
00
43
17
17
0O
the
r U
rin
ary
14
0.5
11
31
13
02
54
0O
va
ry5
51
.90
55
46
90
12
92
41
Va
gin
a1
0.0
01
10
00
10
0V
ulv
a2
0.1
02
11
00
10
0O
the
r F
em
ale
Ge
nita
l2
0.1
02
20
02
00
0P
rosta
te6
62
.36
60
58
80
31
11
16
0T
estis
33
1.1
32
02
76
01
56
50
Bla
dd
er
73
2.5
64
95
61
71
42
21
54
1K
idn
ey &
Re
na
l P
elv
is9
53
.26
13
48
01
52
44
16
17
1E
ye
23
0.8
71
62
03
08
10
11
Bra
in,
CN
S9
13
.14
05
18
38
04
82
33
8T
hyro
id2
84
9.7
69
21
52
54
30
01
46
95
85
Oth
er
En
do
crin
e1
60
.51
06
16
00
52
90
Ho
dg
kin
's L
ym
ph
om
a1
44
4.9
88
56
12
81
60
93
38
51
No
n-H
od
gkin
's L
ym
ph
om
a1
50
5.1
88
63
12
12
90
23
18
77
3U
nkn
ow
n o
r Ill-
De
fin
ed
29
1.0
15
14
22
70
00
02
2
TOTA
L2,
933
100.
013
1716
1425
4339
085
148
778
234
59
21
TAB
LE 5
C
ASE
S SE
EN A
T K
FSH
&R
C B
Y SI
TE, S
EX, C
LASS
OF
CA
SE A
ND
SEE
R S
UM
MAR
Y ST
AGE
20
14
22
22
TA
BLE
6
AN
ALY
TIC
CA
SES
SEEN
AT
KFS
H&
RC
BY
SITE
AN
D A
GE
201
4
SITE
0-4
5-9
10-1
415
-19
20-2
425
-29
30-3
435
-39
40-4
445
-49
50-5
455
-59
60-6
465
-69
70-7
475
-79
80-8
485
+TO
TAL
Oral
Cavit
y0
11
00
62
713
28
88
96
137
1010
1Na
soph
aryn
x1
01
43
31
616
59
60
02
10
058
Esop
hagu
s0
00
00
00
02
01
94
20
71
127
Stom
ach
00
00
20
44
74
114
510
15
12
60Sm
all In
testi
ne0
00
10
10
21
01
13
22
00
014
Colon
00
00
12
95
147
1318
129
74
10
102
Rectu
m &
Rec
tosigm
oid0
01
00
45
17
511
1411
108
12
383
Anus
, Ana
l Can
al, A
nore
ctum
00
01
00
00
10
02
00
01
01
6Liv
er8
11
11
10
06
18
1312
127
02
175
Gallb
ladde
r0
00
00
00
11
05
13
32
10
118
Bile
Ducts
00
00
00
22
00
12
10
11
10
11Pa
ncre
as0
00
10
01
17
29
36
98
20
049
Retro
perito
neum
, Per
itone
um0
00
00
00
01
02
01
00
00
04
Nasa
l Cav
ity, S
inus,
Ear
00
00
00
00
00
02
10
01
00
4La
rynx
00
00
01
02
20
22
31
11
10
16Lu
ng /
Bron
chus
10
00
11
12
74
812
911
100
00
67Pl
eura
00
00
00
00
00
00
00
00
00
0Ot
her R
espir
atory
& T
hora
cic0
00
11
00
00
00
00
00
00
02
Leuk
emia
3717
1922
89
117
132
93
28
13
10
172
Myelo
ma
00
00
00
10
31
16
71
10
00
21Ot
her H
emato
poiet
ic1
00
12
30
04
23
63
11
00
027
Bone
25
1313
55
22
20
02
10
31
00
56So
ft Tiss
ue4
40
92
42
45
01
41
10
10
244
Melan
oma
of Sk
in0
00
00
00
10
10
01
00
00
03
Kapo
sis S
arco
ma
00
00
01
00
00
01
22
41
00
11Ot
her S
kin C
ance
r0
00
26
20
22
23
43
15
52
140
Brea
st0
00
02
630
6970
7163
4537
1714
82
343
7Ce
rvix
Uter
i0
00
01
15
52
36
46
30
01
037
Corp
us U
teri
00
00
11
03
43
1115
1611
54
21
77Ut
erus
NOS
00
00
00
00
00
00
00
00
00
0Ov
ary
02
11
21
22
27
510
24
13
01
46Vu
lva0
00
00
00
00
10
00
00
00
01
Othe
r Fem
ale G
enita
l0
00
01
00
00
00
10
00
00
02
Pros
tate
01
00
00
00
00
69
108
99
42
58Te
stis
00
03
65
54
20
10
00
00
00
26Bl
adde
r2
00
00
11
15
07
144
68
23
256
Kidn
ey &
Ren
al Pe
lvis
135
00
01
23
91
1010
79
35
11
80Ot
her U
rinar
y0
00
00
00
11
11
42
10
00
011
Eye
160
10
01
01
00
00
00
00
10
20Br
ain, C
NS10
107
47
76
64
09
51
12
20
182
Thyr
oid1
01
516
2234
4341
2721
187
410
00
425
4Ot
her E
ndoc
rine
81
11
12
01
00
00
00
10
00
16Ho
dgkin
's Ly
mpho
ma
412
1225
2317
99
72
21
30
01
00
127
Non-
Hodg
kin's
Lymp
hom
a3
05
75
710
916
27
811
79
92
312
0Un
know
n or I
ll-Defi
ned
10
00
00
00
31
35
04
41
00
22
TOTA
L11
259
6410
297
115
145
206
280
157
258
272
205
167
136
9335
4025
43
SIT
E0-
45-
910
-14
15-1
920
-24
25-2
930
-34
35-3
940
-44
45-4
950
-54
55-5
960
-64
65-6
970
-74
75-7
980
-84
85 +
TOTA
L
Ora
l Cav
ity0
11
00
62
713
28
88
96
137
1010
1N
asop
hary
nx1
01
43
31
616
59
60
02
10
058
Eso
phag
us0
00
00
00
02
01
94
20
71
127
Sto
mac
h0
00
02
04
47
411
45
101
51
260
Sm
all I
ntes
tine
00
01
01
02
10
11
32
20
00
14C
olon
00
00
12
95
147
1318
129
74
10
102
Rec
tum
& R
ecto
sigm
oid
00
10
04
51
75
1114
1110
81
23
83A
nus,
Ana
l Can
al, A
nore
ctum
00
01
00
00
10
02
00
01
01
6Li
ver
81
11
11
00
61
813
1212
70
21
75G
allb
ladd
er0
00
00
00
11
05
13
32
10
118
Bile
Duc
ts0
00
00
02
20
01
21
01
11
011
Pan
crea
s0
00
10
01
17
29
36
98
20
049
Ret
rope
riton
eum
, Per
itone
um0
00
00
00
01
02
01
00
00
04
Nas
al C
avity
, Sin
us, E
ar0
00
00
00
00
00
21
00
10
04
Lary
nx0
00
00
10
22
02
23
11
11
016
Lung
/ B
ronc
hus
10
00
11
12
74
812
911
100
00
67P
leur
a0
00
00
00
00
00
00
00
00
00
Oth
er R
espi
rato
ry &
Tho
raci
c0
00
11
00
00
00
00
00
00
02
Leuk
emia
3717
1922
89
117
132
93
28
13
10
172
Mye
lom
a0
00
00
01
03
11
67
11
00
021
Oth
er H
emat
opoi
etic
10
01
23
00
42
36
31
10
00
27B
one
25
1313
55
22
20
02
10
31
00
56S
oft T
issu
e4
40
92
42
45
01
41
10
10
244
Mel
anom
a of
Ski
n0
00
00
00
10
10
01
00
00
03
Kap
osi's
Sar
com
a0
00
00
10
00
00
12
24
10
011
Oth
er S
kin
Can
cer
00
02
62
02
22
34
31
55
21
40B
reas
t0
00
02
630
6970
7163
4537
1714
82
343
7C
ervi
x U
teri
00
00
11
55
23
64
63
00
10
37C
orpu
s U
teri
00
00
11
03
43
1115
1611
54
21
77U
teru
s N
OS
00
00
00
00
00
00
00
00
00
0O
vary
02
11
21
22
27
510
24
13
01
46V
ulva
00
00
00
00
01
00
00
00
00
1O
ther
Fem
ale
Gen
ital
00
00
10
00
00
01
00
00
00
2P
rost
ate
01
00
00
00
00
69
108
99
42
58Te
stis
00
03
65
54
20
10
00
00
00
26B
ladd
er2
00
00
11
15
07
144
68
23
256
Kid
ney
& R
enal
Pel
vis
135
00
01
23
91
1010
79
35
11
80O
ther
Urin
ary
00
00
00
01
11
14
21
00
00
11E
ye16
01
00
10
10
00
00
00
01
020
Bra
in, C
NS
1010
74
77
66
40
95
11
22
01
82Th
yroi
d1
01
516
2234
4341
2721
187
410
00
425
4O
ther
End
ocrin
e8
11
11
20
10
00
00
01
00
016
Hod
gkin
's L
ymph
oma
412
1225
2317
99
72
21
30
01
00
127
Non
-Hod
gkin
's L
ymph
oma
30
57
57
109
162
78
117
99
23
120
Unk
now
n or
Ill-D
efin
ed1
00
00
00
03
13
50
44
10
022
TOTA
L11
259
6410
297
115
145
206
280
157
258
272
205
167
136
9335
4025
43
TA
BL
E 6
AN
AL
YT
IC C
AS
ES
SE
EN
AT
KF
SH
&R
C B
Y S
ITE
AN
D A
GE
201
4
23
23
TABL
E 7
ANAL
YTIC
MAL
E C
ASES
SEE
N AT
KFS
H&RC
BY
SITE
AND
AG
E 20
14
SITE
0-45-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85 +
TOTA
L
Oral
Cavit
y0
10
00
52
57
03
56
53
105
865
Naso
phar
ynx
10
02
33
14
150
65
00
11
00
42Es
opha
gus
00
00
00
00
20
17
11
05
11
19St
omac
h0
00
00
00
16
05
22
41
41
127
Small
Intes
tine
00
01
00
01
00
11
22
20
00
10Co
lon0
00
01
04
19
08
106
63
11
050
Rectu
m &
Recto
sigmo
id0
00
00
45
16
07
87
56
02
253
Anus
, Ana
l Can
al, A
nore
ctum
00
00
00
00
00
01
00
00
00
1Liv
er3
10
01
10
04
03
89
43
01
139
Gallb
ladde
r0
00
00
00
11
00
01
11
10
17
Bile D
ucts
00
00
00
22
00
02
10
11
10
10Pa
ncre
as0
00
00
01
12
07
33
83
10
029
Retro
perito
neum
, Per
itone
um0
00
00
00
01
01
01
00
00
03
Nasa
l Cav
ity, S
inus,
Ear
00
00
00
00
00
02
00
00
00
2La
rynx
00
00
01
02
20
22
31
11
10
16Lu
ng / B
ronc
hus
00
00
11
11
50
68
89
100
00
50Ple
ura
00
00
00
00
00
00
00
00
00
0Ot
her R
espir
atory
& Th
orac
ic0
00
11
00
00
00
00
00
00
02
Leuk
emia
2310
1016
44
63
110
52
25
01
10
103
Myelo
ma0
00
00
01
03
01
45
11
00
016
Othe
r Hem
atopo
ietic
10
01
23
00
30
24
20
10
00
19Bo
ne2
25
74
10
22
00
21
00
10
029
Soft T
issue
13
03
12
22
30
13
10
01
02
25Me
lanom
a of S
kin0
00
00
00
00
00
01
00
00
01
Kapo
sis S
arco
ma0
00
00
10
00
00
02
14
10
09
Othe
r Skin
Can
cer
00
01
41
01
10
13
21
13
21
22Br
east
00
00
00
00
00
00
10
00
00
1Pr
ostat
e0
10
00
00
00
06
910
89
94
258
Testi
s0
00
36
55
42
01
00
00
00
026
Penis
00
00
00
00
00
00
00
00
00
0Ot
her M
ale G
enita
l0
00
00
00
00
00
00
00
00
00
Bladd
er1
00
00
11
14
07
114
58
22
249
Kidne
y & R
enal
Pelvi
s7
00
00
10
29
05
65
72
21
148
Othe
r Urin
ary
00
00
00
00
00
01
00
00
00
1Ey
e5
01
00
00
00
00
00
00
00
06
Brain
, CNS
46
41
43
25
10
20
10
21
01
37Th
yroid
00
10
44
615
91
38
31
70
01
63Ot
her E
ndoc
rine
40
01
12
01
00
00
00
10
00
10Ho
dgkin
's Ly
mpho
ma3
85
1414
107
66
02
13
00
00
079
Non-
Hodg
kin's
Lymp
homa
30
34
33
45
120
34
44
77
21
69Un
know
n or I
ll-Defi
ned
00
00
00
00
10
23
02
21
00
11
TOTA
L58
3229
5554
5650
6712
71
9112
597
8180
5425
2511
07
SITE
0-4
5-9
10-1
415
-19
20-2
425
-29
30-3
435
-39
40-4
445
-49
50-5
455
-59
60-6
465
-69
70-7
475
-79
80-8
485
+TO
TAL
Oral
Cavit
y0
10
00
52
57
03
56
53
105
865
Naso
phar
ynx
10
02
33
14
150
65
00
11
00
42Es
opha
gus
00
00
00
00
20
17
11
05
11
19St
omac
h0
00
00
00
16
05
22
41
41
127
Small
Intes
tine
00
01
00
01
00
11
22
20
00
10Co
lon0
00
01
04
19
08
106
63
11
050
Rectu
m &
Recto
sigmo
id0
00
00
45
16
07
87
56
02
253
Anus
, Ana
l Can
al, A
nore
ctum
00
00
00
00
00
01
00
00
00
1Liv
er3
10
01
10
04
03
89
43
01
139
Gallb
ladde
r0
00
00
00
11
00
01
11
10
17
Bile
Ducts
00
00
00
22
00
02
10
11
10
10Pa
ncre
as0
00
00
01
12
07
33
83
10
029
Retro
perito
neum
, Per
itone
um0
00
00
00
01
01
01
00
00
03
Nasa
l Cav
ity, S
inus,
Ear
00
00
00
00
00
02
00
00
00
2La
rynx
00
00
01
02
20
22
31
11
10
16Lu
ng / B
ronc
hus
00
00
11
11
50
68
89
100
00
50Pl
eura
00
00
00
00
00
00
00
00
00
0Ot
her R
espir
atory
& Th
orac
ic0
00
11
00
00
00
00
00
00
02
Leuk
emia
2310
1016
44
63
110
52
25
01
10
103
Myelo
ma0
00
00
01
03
01
45
11
00
016
Othe
r Hem
atopo
ietic
10
01
23
00
30
24
20
10
00
19Bo
ne2
25
74
10
22
00
21
00
10
029
Soft T
issue
13
03
12
22
30
13
10
01
02
25Me
lanom
a of S
kin0
00
00
00
00
00
01
00
00
01
Kapo
si's S
arco
ma0
00
00
10
00
00
02
14
10
09
Othe
r Skin
Can
cer
00
01
41
01
10
13
21
13
21
22Br
east
00
00
00
00
00
00
10
00
00
1Pr
ostat
e0
10
00
00
00
06
910
89
94
258
Testi
s0
00
36
55
42
01
00
00
00
026
Penis
00
00
00
00
00
00
00
00
00
0Ot
her M
ale G
enita
l0
00
00
00
00
00
00
00
00
00
Blad
der
10
00
01
11
40
711
45
82
22
49Ki
dney
& R
enal
Pelvi
s7
00
00
10
29
05
65
72
21
148
Othe
r Urin
ary
00
00
00
00
00
01
00
00
00
1Ey
e5
01
00
00
00
00
00
00
00
06
Brain
, CNS
46
41
43
25
10
20
10
21
01
37Th
yroid
00
10
44
615
91
38
31
70
01
63Ot
her E
ndoc
rine
40
01
12
01
00
00
00
10
00
10Ho
dgkin
's Ly
mpho
ma3
85
1414
107
66
02
13
00
00
079
Non-
Hodg
kin's
Lymp
homa
30
34
33
45
120
34
44
77
21
69Un
know
n or I
ll-Defi
ned
00
00
00
00
10
23
02
21
00
11
TOTA
L58
3229
5554
5650
6712
71
9112
597
8180
5425
2511
07
TAB
LE 7
AN
ALYT
IC M
ALE
CAS
ES S
EEN
AT
KFS
H&
RC
BY
SITE
AN
D A
GE
2014
24
SITE
0-4
5-9
10-1
415
-19
20-2
425
-29
30-3
435
-39
40-4
445
-49
50-5
455
-59
60-6
465
-69
70-7
475
-79
80-8
485
+TO
TAL
Ora
l Cav
ity0
01
00
10
26
25
32
43
32
236
Naso
phar
ynx
00
12
00
02
15
31
00
10
00
16Es
opha
gus
00
00
00
00
00
02
31
02
00
8St
omac
h0
00
02
04
31
46
23
60
10
133
Smal
l Int
estin
e0
00
00
10
11
00
01
00
00
04
Colo
n0
00
00
25
45
75
86
34
30
052
Rect
um &
Rec
tosig
moi
d0
01
00
00
01
54
64
52
10
130
Anus
, Ana
l Can
al, A
nore
ctum
00
01
00
00
10
01
00
01
01
5Li
ver
50
11
00
00
21
55
38
40
10
36G
allb
ladd
er0
00
00
00
00
05
12
21
00
011
Bile
Duc
ts0
00
00
00
00
01
00
00
00
01
Panc
reas
00
01
00
00
52
20
31
51
00
20Re
trope
riton
eum
, Per
itone
um0
00
00
00
00
01
00
00
00
01
Nasa
l Cav
ity, S
inus
, Ear
00
00
00
00
00
00
10
01
00
2La
rynx
00
00
00
00
00
00
00
00
00
0Lu
ng /
Bron
chus
10
00
00
01
24
24
12
00
00
17Pl
eura
00
00
00
00
01
00
00
00
00
0O
ther
Res
pira
tory
& T
hora
cic0
00
00
00
00
00
00
10
00
00
Leuk
emia
147
96
45
54
22
41
03
12
00
69M
yelo
ma
00
00
00
00
01
02
20
00
00
5O
ther
Hem
atop
oiet
ic0
00
00
00
01
21
21
10
00
08
Bone
03
86
14
20
00
00
00
30
00
27So
ft Ti
ssue
31
06
12
02
20
01
01
00
00
19M
elan
oma
of S
kin0
00
00
00
10
10
00
00
00
02
Kapo
si's
Sarc
oma
00
00
00
00
00
01
01
00
00
2O
ther
Skin
Can
cer
00
01
21
01
12
21
10
42
00
18Br
east
00
00
26
3069
7071
6345
3617
148
23
436
Cerv
ix Ut
eri
00
00
11
55
23
64
63
00
10
37Co
rpus
Ute
ri0
00
01
10
34
311
1516
115
42
177
Uter
us N
OS
00
00
00
00
00
00
00
00
00
0O
vary
02
11
21
22
27
510
24
13
01
46Vu
lva0
00
00
00
00
10
00
00
00
01
Oth
er F
emal
e G
enita
l0
00
01
00
00
00
10
00
00
02
Blad
der
10
00
00
01
00
03
01
00
10
7Ki
dney
& R
enal
Pel
vis6
50
00
02
10
15
42
21
30
032
Oth
er U
rinar
y0
00
00
00
11
11
32
10
00
010
Eye
110
00
01
01
00
00
00
00
10
14Br
ain,
CNS
64
33
34
41
30
75
01
01
00
45Th
yroi
d1
00
512
1828
2832
2618
104
33
00
319
1O
ther
End
ocrin
e4
11
00
00
00
00
00
00
00
06
Hodg
kin's
Lym
phom
a1
47
119
72
31
20
00
00
10
048
Non-
Hodg
kin's
Lym
phom
a0
02
32
46
44
24
47
32
20
251
Unkn
own
or Ill
-Def
ined
10
00
00
00
21
12
02
20
00
11
TOTA
L54
2735
4743
5995
140
152
157
167
147
108
8756
3910
1514
36
25
26
2727
FIGURE 11
DISTRIBUTION OF PEDIATRIC MALIGNANCIES 2014 ANALYTIC CASES (TOTAL CASES = 219)
FIGURE 12
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY 2014 ANALYTIC CASES (TOTAL CASES = 219)
27
FIGURE 11
DISTRIBUTION OF PEDIATRIC MALIGNANCIES 2014 ANALYTIC CASES (TOTAL CASES = 219)
FIGURE 12
DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY 2014 ANALYTIC CASES (TOTAL CASES = 219)
2828
TABLE 10
PRIMARY SITE TABLE 2014 (INCLUDES MULTIPLE PRIMARIES)
SITE HISTOLOGY ALL
CASES ADULTS PEDIATRICS
(NOS - Not Otherwise Specified) MALE FEMALE MALE FEMALE 2,933 1189 1,485 128 130
LIP 6 4 2 0 0 Squamous Cell Carcinoma 5 3 2 0 0 Basal Cell Carcinoma 1 1 0 0 0
TONGUE 30 18 12 0 0 Squamous Cell Carcinoma 29 17 12 0 0 Mucoepidermoid Carcinoma 1 1 0 0 0
GUM 11 5 6 0 0 Squamous Cell Carcinoma 10 5 5 0 0 Malignant Melanoma 1 0 1 0 0
FLOOR OF MOUTH 4 4 0 0 0 Squamous Cell Carcinoma 4 4 0 0 0
OROPHARYNX 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0
SALIVARY GLANDS, MAJOR 9 8 1 0 0 Mucoepidermoid Carcinoma 3 2 1 0 0 Adenoid Cystic Carcinoma 3 3 0 0 0 Large Cell Neuroendocrine Carcinoma 1 1 0 0 0 Carcinoma NOS 1 1 0 0 0 Hemangiosarcoma 1 1 0 0 0
TONSIL 2 2 0 0 0 Squamous Cell Carcinoma 2 2 0 0 0
NASOPHARYNX 59 42 15 1 1 Squamous Cell Carcinoma 49 34 14 0 1 Carcinoma Undifferentiated 7 6 1 0 0 Embryonal Rhabdomyosarcoma 1 0 0 1 0 Carcinoma NOS 2 2 0 0 0
HYPOPHARYNX 7 1 5 0 1 Squamous Cell Carcinoma 6 1 5 0 0 Rhabdomyosarcoma 1 0 0 0 1
OTHER SITES IN LIP, ORAL CAVITY, PHARYNX 2 0 1 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Carcinoma 1 0 1 0 0
ESOPHAGUS 30 21 9 0 0 Squamous Cell Carcinoma 8 3 5 0 0 Adenocarcinoma NOS 18 15 3 0 0 Carcinoma NOS 2 1 1 0 0 Adenosquamous Carcinoma 0 2 0 0
2929
STOMACH 74 36 38 0 0
Adenocarcinoma NOS 45 27 18 0 0 Carcinoma Diffuse Type 6 2 4 0 0 Signet Ring Cell Carcinoma 17 5 12 0 0 Gastrointestinal Stromal Sarcoma 4 0 4 0 0 Neuroendocrine Carcinoma 1 1 0 0 0 Carcinoid 1 1 0 0 0
SMALL INTESTINE 20 14 6 0 0 Neuroendocrine Tumor 2 1 1 0 0 Adenocarcinoma NOS 11 7 4 0 0 Carcinoid Tumor 3 3 0 0 0 Mucinous Adenocarcinoma 1 0 1 0 0 Gastro Intestinal Stromal Sarcoma 3 3 0 0 0
COLON 130 64 66 0 0 Adenocarcinoma NOS 104 53 51 0 0 Mucinous Adenocarcinoma 14 7 7 0 0 Signet Ring Cell Carcinoma 2 1 1 0 0 Carcinoma NOS 4 2 2 0 0 Neoplasm Malignant 2 1 1 0 0 GI Stromal Sarcoma 2 0 2 0 0 Neuroendocrine Carcinoma 2 0 2 0 0
RECTOSIGMOID JUNCTION 16 12 4 0 0 Adenocarcinoma NOS 15 11 4 0 0 Neuroendocrine Carcinoma 1 1 0 0 0
RECTUM 84 52 31 0 1 Adenocarcinoma NOS 78 48 29 0 1 Mucinous Adenocarcinoma 4 3 1 0 0 Carcinoma 2 1 1 0 0
ANUS, ANAL CANAL, ANORECTUM 7 2 5 0 0 Adenocarcinoma 2 0 2 0 0 Squamous Cell Carcinoma 5 2 3 0 0
LIVER, INTRAHEPATIC BILE DUCT 80 40 30 4 6 Hepatocellular Carcinoma 59 30 26 1 2 Cholangiocarcinoma 8 5 3 0 0 Hepatoblastoma 7 0 0 3 4 Carcinoma NOS 1 1 0 0 0 Adenocarcinoma NOS 3 3 0 0 0 Klatskin Tumor 1 1 0 0 0 Kupffer Cell Sarcoma 1 0 1 0 0
GALLBLADDER, EXTRAHEPATIC BILE DUCT 22 7 15 0 0 Adenocarcinoma NOS 14 3 11 0 0 Carcinoma 4 1 3 0 0 Cholangiocarcinoma 4 3 1 0 0
PANCREAS 59 37 22 0 0 Adenocarcinoma NOS 38 28 10 0 0
3030
Neoplasm Malignant 4 1 3 0 0 Carcinoma NOS 10 5 5 0 0 Carcinoid 3 1 2 0 0 Infiltrating Duct Carcinoma 1 1 0 0 0 Mucinous Adenocarcinoma 3 1 2 0 0
NASAL CAVITY, MIDDLE EAR 4 2 2 0 0 Basaloid Squamous Cell Carcinoma 1 1 0 0 0 Adenoid Cystic Carcinoma 2 1 1 0 0 Neoplasm Malignant 1 0 1 0 0
LARYNX 18 18 0 0 0 Squamous Cell Carcinoma 18 18 0 0 0
LUNG, BRONCHUS 91 72 19 0 0 Adenocarcinoma NOS 41 33 8 0 0 Mucinous Adenocarcinoma 3 2 1 0 0 Mucoepidermoid Carcinoma 1 1 0 0 0 Carcinoid 4 1 3 0 0 Carcinoma NOS 5 5 0 0 0 Neoplasm Malignant 2 1 1 0 0 Rhabdomyosarcoma 1 1 0 0 0 Non-Small Cell Carcinoma 16 12 4 0 0 Small Cell Carcinoma 4 4 0 0 0 Squamous Cell Carcinoma 14 12 2 0 0
THYMUS 1 1 0 0 0 Thymoma Malignant 1 1 0 0 0
HEART 0 0 0 0 0 Synovial Sarcoma 0 0 0 0 0
BONE, JOINTS, CARTILAGE 63 24 18 10 11 Osteosarcoma 23 8 6 4 5 Chondroblastic Osteosarcoma 7 2 3 0 2 Ewing Sarcoma 11 3 2 4 2 Chordoma 1 0 1 0 0 Chondrosarcoma 2 1 1 0 0 Giant Cell Tumor of Bone 2 2 0 0 0 Hemangiosarcoma 1 0 1 0 0 Malignant Rhabdoid Tumor 1 0 0 1 0 Myxoid Chondrosarcoma 1 1 0 0 0 Periosteal Osteosarcoma 1 0 1 0 0 Primitive Neuroectodermal Tumor 2 0 0 1 1 Sarcoma NOS 5 2 2 0 1 Others 6 5 1 0 0
BONE MARROW 209 80 49 48 31 Precursor B-Cell Lymphoblastic Leukemia 51 1 5 29 16 Acute Myeloid Leukemia 56 23 17 7 9 Chronic Myeloid Leukemia 24 10 12 2 0 Precursor T-Cell Lymphoblastic Leukemia 22 13 2 7 0 Acute Monocytic Leukemia 1 1 0 0 0
3131
Acute Promyelocytic Leukemia 6 2 1 3 0
B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
10 6 0 0 0
Hairy Cell Leukemia 1 1 0 0 0 Burkitt Cell Leukemia 3 2 0 0 1 Myelodysplastic Syndrome Polycythemia Vera 6 5 1 0 0 Precursor Cell Lymphoblastic Leukemia 3 0 0 0 3 Polymorphocytic Leukemia B Cell Type 1 1 0 0 0 Acute Myelomonocytic Leukemia 7 3 3 0 1
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
11 6 5 0 0
Acute Leukemia 4 1 1 0 1 Hypereosinophilic Syndrome 1 1 0 0 0 Acute Megakaryoblastic Leukemia 1 1 0 0 0 Essential Thrombocythemia 4 2 2 0 0 Refractory Anemia with Excess Blasts 1 1 0 0 0
MULTIPLE MYELOMA 26 20 6 0 0 Multiple Myeloma 26 20 6 0 0
SPLEEN 2 1 1 0 0 Non-Hodgkin's Lymphoma 2 1 1 0 0
SKIN (NON MELANOMA) 45 26 19 0 0 Squamous Cell Carcinoma 12 7 5 0 0 Basal Cell Carcinoma 23 13 10 0 0 Dermatofibrosarcoma 4 2 2 0 0 Sebacious Adenocarcinoma 1 0 1 0 0 Clear Cell Adenocarcinoma 1 1 0 0 0 Verrucous Carcinoma 1 1 0 0 0 Basosquamous Carcinoma 1 0 1 0 0 Hemangiosarcoma 1 1 0 0 0 Merkel Cell Carcinoma 1 1 0 0 0
RETROPERITONEUM, PERITONEUM 5 3 2 0 0 Carcinoid Tumor 1 1 0 0 0 Mucinous Adenocarcinoma 1 1 0 0 0 Desmoplastic Round Cell Tumor 1 0 1 0 0 Leiomyosarcoma 1 1 0 0 0 Neuroendocrine Carcinoma 1 0 1 0 0
CONNECTIVE, SUBCUTEANEOUS, SOFT TISSUES
61 32 18 6 5
Synovial Sarcoma 7 4 2 1 0 Neuroblastoma 3 0 0 0 3 Dermatofibrosarcoma NOS 4 4 0 0 0 Embryonal Rhabdomyosarcoma 2 0 0 2 0 Ganglioneuroblastoma 1 0 0 1 0 Myxoid Liposarcoma 3 2 1 0 0 Fibromyxosarcoma 4 2 2 0 0 Spindle Cell Sarcoma 2 1 1 0 0 Undifferentiated Sarcoma 1 1 0 0 0
3232
Gastrointestinal Stromal Sarcoma 1 1 0 0 0 Leiomyosarcoma 5 3 2 0 0 Malignant Peripheral Nerve Sheath Tumor 4 2 1 0 1 Round Cell Liposarcoma 1 0 1 0 0 Rhabdomyosarcoma 4 0 1 2 1 Clear Cell Sarcoma 1 1 0 0 0 Dedifferentiated Liposarcoma 2 2 0 0 0 Epithelioid Sarcoma 1 0 1 0 0 Ewing Sarcoma 1 0 1 0 0 Malignant Granular Cell Tumor 1 0 1 0 0 Malignant Fibrous Histiocytoma 1 1 0 0 0 Malignant Mesothelioma 1 1 0 0 0 Myxoid Chondrosarcoma 1 1 0 0 0 Giant Cell Sarcoma 2 2 0 0 0 PNET 1 0 1 0 0 Small Cell Sarcoma 1 0 1 0 0 Basal Cell Nodular Carcinoma 1 1 0 0 0 Chondroblastic Sarcoma NOS 1 1 0 0 0 Carcinoma NOS 1 1 0 0 0 Sarcoma NOS 3 1 2 0 0
BREAST 466 1 465 0 0 Infiltrating Duct Carcinoma 373 1 372 0 0 Lobular Carcinoma 38 0 38 0 0 Intraductal Carcinoma Noninfiltrating 20 0 20 0 0 Infiltrating Duct Mixed with Other Types of Ca 10 0 10 0 0
Infiltrating Lobular Mixed with Other Types of Ca
1 0 1 0 0
Carcinoma NOS 2 0 2 0 0 Metaplastic Carcinoma 3 0 3 0 0 Phyllodes Tumor Malignant 4 0 4 0 0 Infiltrating Duct and Lobular Carcinoma 5 0 5 0 0 Cribriform Carcinoma In Situ 2 0 2 0 0 Paget Disease Mammary 1 0 1 0 0 Malignant Neoplasm 2 0 2 0 0 Clear Cell Sarcoma NOS 1 0 1 0 0 Intraductal Papillary Carcinoma 1 0 1 0 0 DCIS Mixed With Other In Situ 1 0 1 0 0 Adenocarcinoma NOS 2 0 2 0 0
VULVA 2 0 2 0 0 Squamous Cell Carcinoma Keratinizing 1 0 1 0 0 Squamous Intraepithelial Neoplasia Grade III 1 0 1 0 0
VAGINA 1 0 1 0 0 Squamous Cell Carcinoma 1 0 1 0 0
CERVIX UTERI 43 0 43 0 0 Squamous Cell Carcinoma 26 0 26 0 0 Adenocarcinoma 5 0 5 0 0 Serous Cyst Adenocarcinoma 1 0 1 0 0 Adenosarcoma 1 0 1 0 0 Clear Cell Adenocarcinoma 1 0 1 0 0
3333
Leiomyosarcoma 1 0 1 0 0 Squamous Intraepithelial Neoplasia Grade III 7 0 7 0 0 Mucinous Adenocarcinoma 1 0 1 0 0
CORPUS UTERI 85 0 85 0 0 Endometrioid Adenocarcinoma 58 0 58 0 0 Adenocarcinoma NOS 6 0 6 0 0 Adenocarcinoma with mixed subtypes 1 0 1 0 0 Serous Cystadenocarcinoma 4 0 4 0 0 Clear Cell Adenocarcinoma 4 0 4 0 0 Endometrial Stromal Sarcoma 1 0 1 0 0 Carcinosarcoma 2 0 2 0 0 Mullerian Mixed Tumor 5 0 5 0 0 Mucinous Adenocarcinoma 1 0 1 0 0 Squamous Cell Carcinoma 1 0 1 0 0 Carcinoma NOS 2 0 2 0 0
UTERUS, NOS 13 0 13 0 0 Carcinosarcoma 3 0 3 0 0 Carcinoma NOS 1 0 1 0 0 Mullerian Mixed Tumor 2 0 2 0 0 Serous Cystadenocarcinoma 2 0 2 0 0 Spindle Cell Sarcoma 1 0 1 0 0 Leiomyosarcoma 4 0 4 0 0
OVARY 54 0 51 0 3 Serous Cystadenocarcinoma 23 0 23 0 0 Papillary Serous Cystadenocarcinoma 5 0 5 0 0 Adenocarcinoma NOS 4 0 4 0 0 Dysgerminoma 1 0 1 0 0 Germinoma 1 0 0 0 1 Mullerian Mixed Tumor 1 0 1 0 0 Mucinous Adenocarcinoma 3 0 3 0 0 Mucinous Cystadenocarcinoma 1 0 1 0 0 Carcinoma NOS 1 0 1 0 0 Clear Cell Adenocarcinoma 4 0 4 0 0 Endometrioid Adenocarcinoma 3 0 3 0 0 Neoplasm Malignant 2 0 2 0 0 Sertoli-Leydig Cell Tumor 1 0 1 0 0 Papillary Cystadenocarcinoma 1 0 1 0 0 Yolk Sac Tumor 1 0 0 0 1 Trophoblastic Epithelioid Tumor 1 0 1 0 0 Teratoma Malignant 1 0 0 0 1
PLACENTA 2 0 2 0 0 Trophoblastic Placenta 2 0 2 0 0
PROSTATE 66 65 0 1 0 Adenocarcinoma NOS 60 60 0 0 0 Carcinoma NOS 2 2 0 0 0 Neoplasm Malignant 2 2 0 0 0 Embryonal Rhabdomyosarcoma 1 0 0 1 0 Small Cell Carcinoma 1 1 0 0 0
3434
TESTIS* 33 32 0 0 0
Seminoma 15 15 0 0 0 Mixed Germ Cell Tumor 8 8 0 0 0 Hemangiosarcoma 2 2 0 0 0 Embryonal Carcinoma 1 0 0 0 0 Germinoma 2 2 0 0 0 Liposarcoma 1 1 0 0 0 Taratoma 3 0 0 0 0
KIDNEY AND RENAL PELVIS 95 54 23 7 11 Nephroblastoma 16 0 0 6 10 Clear Cell Adenocarcinoma 28 21 7 0 0 Papillary Adenocarcinoma 4 4 0 0 0 Renal Cell Carcinoma 27 14 12 0 1 Renal Cell Carcinoma Chromophobe Type 11 9 2 0 0 Renal Cell Carcinoma Sarcomatoid 1 1 0 0 0 Transitional Cell Carcinoma 2 2 0 0 0 Papillary Transitional Cell Carcinoma 2 2 0 0 0 Papillary TCC Non-Invasive 2 0 2 0 0 Spindle Cell Carcinoma 1 1 0 0 0 Malignant Rhabdoid Tumor 1 0 0 1 0
URINARY BLADDER 73 63 8 1 1 Papillary Transitional Cell Carcinoma 53 51 2 0 0 Transitional Cell Carcinoma 12 9 3 0 0 Squamous Cell Carcinoma 3 2 1 0 0 Mucinous Adenocarcinoma 1 0 1 0 0 Transitional Cell Carcinoma Spindle Cell 1 0 1 0 0 Rhabdomyosarcoma 1 0 0 1 0 Pseudosarcomatous Carcinoma 1 1 0 0 0 Embryonal Rhabdomyosarcoma 1 0 0 0 1
EYE, ADNEXA 23 1 3 6 13 Retinoblastoma 16 0 0 5 11 Adenoid Cystic Carcinoma 1 0 1 0 0 Rhabdomyosarcoma 2 0 0 1 1 Sebaceous Adenocarcinoma 1 0 1 0 0 Lymphoepithelial Carcinoma 1 0 1 0 0 Basal Cell Carcinoma 1 1 0 0 0 Orbital Sarcoma 1 0 0 0 1
MENINGES 2 0 2 0 0 Meningioma Malignant 2 0 2 0 0
BRAIN 91 29 31 14 17 Glioblastoma 17 8 8 1 0 Medulloblastoma 11 6 3 0 2 Glioma Malignant 11 2 1 1 7 Oligodendroglioma 7 1 6 0 0 Pilocytic Astrocytoma 1 0 0 0 1 Atypical Teratoid/Rhabdoid Tumor 1 0 0 0 1 Ependymoma Anaplastic 2 0 0 1 1
3535
Oligodendroglioma Anaplastic 6 3 3 0 0 Papillary Ependymoma 1 0 0 1 0 Ependymoma 7 3 2 1 1 Germinoma 3 1 1 1 0 Mixed Glioma 5 2 3 0 0 Astrocytoma Anaplastic 1 0 0 1 0 Astrocytoma 4 1 0 1 2 Desmoplastic Nodular Medulloblastoma 1 1 0 0 0 Medulloblastoma 11 0 3 6 2 Gliosarcoma 1 1 0 0 0 Pleomorphic Xanthoastrocytoma 1 0 1 0 0
THYROID 284 68 215 1 0 Papillary Adenocarcinoma 102 28 74 0 0 Papillary Carcinoma Columnar Cell 38 8 30 0 0 Papillary Carcinoma Follicular Variant 54 12 42 0 0 Papillary Carcinoma 6 2 4 0 0 Papillary Microcarcinoma 33 6 27 0 0 Papillary Carcinoma Encapsulated 23 5 18 0 0 Follicular Adenocarcinoma 5 2 3 0 0 Carcinoma Anaplastic 3 0 3 0 0 Medullary Carcinoma 6 2 4 0 0 Oxyphilic Adenocarcinoma 13 3 9 1 0 Non Encapsulating Sclerosing Carcinoma 1 0 1 0 0
ADRENAL GLAND 11 2 0 4 5 Neuroblastoma 9 0 0 4 5 Adrenal Cortical Carcinoma 2 2 0 0 0
OTHER ENDOCRINE GLANDS 3 3 0 0 0 Pineoblastoma 2 2 0 0 0 Germinoma 1 1 0 0 0
LYMPH NODES (HODGKIN'S LYMPHOMA) 144 72 43 16 13 Nodular Sclerosis 88 39 28 9 12 Hodgkin's Lymphoma NOS 20 9 9 2 0 Mixed Cellularity 18 13 2 2 1 Nodular Lymphocyte Predominance 18 11 4 3 0
LYMPH NODES (NON HODGKIN'S LYMPHOMA) 150 80 59 7 4 Large B-Cell Diffuse 88 50 34 3 1 Follicular Lymphoma 14 10 4 0 0 Burkitt Lymphoma 5 0 1 3 1 Non-Hodgkin's Lymphoma NOS 12 6 6 0 0
Anaplastic Large Cell Lymphoma T Cell and Null Cell Type
1 1 0 0 0
Precursor Lymphoblastic Lymphoma NOS 1 0 0 0 1 Mantle Cell Lymphoma 2 2 0 0 0 Marginal Zone B-Cell Lymphoma 5 1 4 0 0 Mature T-Cell Lymphoma NOS 4 3 1 0 0 Mycosis Fungoides (Skin) 17 6 9 1 1 T-Cell Rich Large B-Cell Lymphoma 1 1 0 0 0
3636
PRIMARY UNKNOWN 29 15 13 0 1 Adenocarcinoma NOS 9 4 5 0 0 Carcinoma NOS 6 4 2 0 0 Neuroblastoma 1 0 0 0 1 Carcinoid Tumor 1 1 0 0 0 Mucinous Adenocarcinoma 3 2 1 0 0 Neoplasm Malignant 4 1 3 0 0 Neuroendocrine Carcinoma 4 2 2 0 0 Squamous Cell Carcinoma 1 1 0 0 0
* One Pediatric Transgender Case for Testicular Cancer was excluded from this analysis
37
TABLE 11
MULTIPLE PRIMARY SITES TABLE2 0 1 4
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
190 68 122
LIP 1 0 1Basal Cell Carcinoma* Skin - Malignant Melanoma 1 0 0
Skin -Basal Cell Carcinoma TONGUE 9 4 5
Squamous Cell Carcinoma Non-Hodgkin's Lymphoma 1 0 1Squamous Cell Carcinoma Non-Hodgkin's Lymphoma 1 1 0Squamous Cell Carcinoma Gum - Squamous Cell Carcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx-SCC 1 0 1Squamous Cell Carcinoma Thyroid - Papillary Carcinoma 1 1 0Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 0 1Squamous Cell Carcinoma* Gum - Squamous Cell Carcinoma 1 0 1
Colon - Mucinous AdenocarcinomaSquamous Cell Carcinoma Thyroid - Papillary Thyroid Microcarcinoma 1 1 0Squamous Cell Carcinoma Nasopharynx - Carcinoma, Undifferentiated 1 1 0
NASOPHARYNX 4 3 1Squamous Cell Carcinoma Bone Marrow - CML 1 1 0Squamous Cell Carcinoma Thyroid - Papillary Microcarcinoma, 1 0 1Squamous Cell Carcinoma Rectum - Adenocarcinoma 1 1 0Squamous Cell Carcinoma** Thyroid - Papillary Microcarcinoma 1 1 0
Glottis - Squamous Cell CarcinomaRetromolar Area - SCC
MOUTH 9 4 5Squamous Cell Carcinoma Tongue - Squamous Cell Carcinoma 1 0 1Squamous Cell Carcinoma Cheek Mucosa - SCC 1 1 0Polymorphous Adenocarcinoma Thyroid - Papillary Microcarcinoma 1 0 1Mucoepidermoid Carcinoma Cheek - Mucoepidermoid Carcinoma 1 0 1Squamous Cell Carcinoma Tonsil-SCC 1 1 0Polymorphous Adenocarcinoma Thyroid - Papillary Microcarcinoma 1 0 1Mucoepidermoid Carcinoma Cheek - Mucoepidermoid Carcinoma 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Squamous Cell Carcinoma Tongue - SCC 1 1 0
GUM 2 0 2Squamous Cell Carcinoma* Tongue - Squamous Cell Carcinoma 1 0 1Squamous Cell Carcinoma* Floor of Mouth - SCC 1 0 1
PHARYNX 1 1 0Squamous Cell Carcinoma Nasopharynx - Squamous Cell Ca 1 1 0
EYE 1 1 0Basal Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 1 0
ESOPHAGUS 4 1 3Adenocarcinoma Kidney - Renal Cell Carcinoma, 1 0 1Squamous Cell Carcinoma Stomach - GIST 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Undifferentiated NHL 1 0 1
STOMACH 3 3 0Neuroendocrine Carcinoma Thyroid - Papillary Ca Follicular 1 1 0Signet Ring Cell Carcinoma Esophagus - Sq Cell Carcinoma 1 1 0
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
38
Therapy-Related AML HL - Nodular Sclerosis 1 1 0Refractory Anemia Acute Myeloid Leukemia 1 1 0
SOFT TISSUE 2 1 1Dermatofibrosarcoma* Skin - Basal Cell Carcinoma 1 1 0
Skin- Squamaous Cell Ca 1 0 1Round Cell Liposarcoma Thyroid - Papillary Carcinoma
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
SKIN 6 3 3Basal Cell Carcinoma Nodular Skin - Basal Cell Carcinoma 1 1 0Basal Cell Carcinoma Skin Lt Temple - Malignant Melanoma 1 0 1Basal Cell Car Nodular*** Skin - Basal Cell Carcinoma 1 0 1
Cheek-Basal Cell CarcinomaSkin Nose - Basal Cell CarcinomaBreast - Malignant phyllodes Tumor
Basal Cell Ca Nodular Skin Scalp/Neck - Basal Cell Carcinoma, 1 0 1Basal Cell Adenocarcinoma** Skin, Lt Nose - Basal Cell Carcinoma 1 1 0
Skin Contra Cheek - Basal Cell CarcinomaSkin: Supraclav Area - Basal Cell Ca
Basal Cell Adenocarcinoma* Skin - Mycosis Fugioides 1 1 0Malignant Lymhpoma Large B-Cell
BRAIN 1 1 0Gliosarcoma Brain - Medulloblastoma 1 1 0
BREAST 48 0 48Lobular Carcinoma Cont Breast - Ductal Ca 1 0 1Intraductal Carcinoma Breast - DCIS 1 0 1Lobular Carcinoma Cont Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Mixed Ca Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Rt Breast - Infiltrating Ductal Ca 1 0 1Lobular Carcinoma Bone Marrow - AML 1 0 1Infiltrating Duct Carcinoma* Tongue - SCC 1 0 1
Cont Breast - Ductal CarcinomaInfiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma In Situ 1 0 1Intraductal Carcinoma Noninfilt Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Intraductal Papillary 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Contra Breast - Ductal Carcinoma
Thyroid - Papillary Thyroid CaInfiltrating Duct Carcinoma Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Colon - Mucinous Adenocarcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Metaplastic Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Contra Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cervix Uteri - Carcinoma In-Situ 1 0 1Lobular Carcinoma In Situ Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Therapy-Related AML HL - Nodular Sclerosis 1 1 0Refractory Anemia Acute Myeloid Leukemia 1 1 0
SOFT TISSUE 2 1 1Dermatofibrosarcoma* Skin - Basal Cell Carcinoma 1 1 0
Skin- Squamaous Cell Ca 1 0 1Round Cell Liposarcoma Thyroid - Papillary Carcinoma
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
SKIN 6 3 3Basal Cell Carcinoma Nodular Skin - Basal Cell Carcinoma 1 1 0Basal Cell Carcinoma Skin Lt Temple - Malignant Melanoma 1 0 1Basal Cell Car Nodular*** Skin - Basal Cell Carcinoma 1 0 1
Cheek-Basal Cell CarcinomaSkin Nose - Basal Cell CarcinomaBreast - Malignant phyllodes Tumor
Basal Cell Ca Nodular Skin Scalp/Neck - Basal Cell Carcinoma, 1 0 1Basal Cell Adenocarcinoma** Skin, Lt Nose - Basal Cell Carcinoma 1 1 0
Skin Contra Cheek - Basal Cell CarcinomaSkin: Supraclav Area - Basal Cell Ca
Basal Cell Adenocarcinoma* Skin - Mycosis Fugioides 1 1 0Malignant Lymhpoma Large B-Cell
BRAIN 1 1 0Gliosarcoma Brain - Medulloblastoma 1 1 0
BREAST 48 0 48Lobular Carcinoma Cont Breast - Ductal Ca 1 0 1Intraductal Carcinoma Breast - DCIS 1 0 1Lobular Carcinoma Cont Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Mixed Ca Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Rt Breast - Infiltrating Ductal Ca 1 0 1Lobular Carcinoma Bone Marrow - AML 1 0 1Infiltrating Duct Carcinoma* Tongue - SCC 1 0 1
Cont Breast - Ductal CarcinomaInfiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma In Situ 1 0 1Intraductal Carcinoma Noninfilt Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Intraductal Papillary 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Contra Breast - Ductal Carcinoma
Thyroid - Papillary Thyroid CaInfiltrating Duct Carcinoma Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Colon - Mucinous Adenocarcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Metaplastic Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Contra Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cervix Uteri - Carcinoma In-Situ 1 0 1Lobular Carcinoma In Situ Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
39
Therapy-Related AML HL - Nodular Sclerosis 1 1 0Refractory Anemia Acute Myeloid Leukemia 1 1 0
SOFT TISSUE 2 1 1Dermatofibrosarcoma* Skin - Basal Cell Carcinoma 1 1 0
Skin- Squamaous Cell Ca 1 0 1Round Cell Liposarcoma Thyroid - Papillary Carcinoma
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
SKIN 6 3 3Basal Cell Carcinoma Nodular Skin - Basal Cell Carcinoma 1 1 0Basal Cell Carcinoma Skin Lt Temple - Malignant Melanoma 1 0 1Basal Cell Car Nodular*** Skin - Basal Cell Carcinoma 1 0 1
Cheek-Basal Cell CarcinomaSkin Nose - Basal Cell CarcinomaBreast - Malignant phyllodes Tumor
Basal Cell Ca Nodular Skin Scalp/Neck - Basal Cell Carcinoma, 1 0 1Basal Cell Adenocarcinoma** Skin, Lt Nose - Basal Cell Carcinoma 1 1 0
Skin Contra Cheek - Basal Cell CarcinomaSkin: Supraclav Area - Basal Cell Ca
Basal Cell Adenocarcinoma* Skin - Mycosis Fugioides 1 1 0Malignant Lymhpoma Large B-Cell
BRAIN 1 1 0Gliosarcoma Brain - Medulloblastoma 1 1 0
BREAST 48 0 48Lobular Carcinoma Cont Breast - Ductal Ca 1 0 1Intraductal Carcinoma Breast - DCIS 1 0 1Lobular Carcinoma Cont Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Mixed Ca Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Rt Breast - Infiltrating Ductal Ca 1 0 1Lobular Carcinoma Bone Marrow - AML 1 0 1Infiltrating Duct Carcinoma* Tongue - SCC 1 0 1
Cont Breast - Ductal CarcinomaInfiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma In Situ 1 0 1Intraductal Carcinoma Noninfilt Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Intraductal Papillary 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Contra Breast - Ductal Carcinoma
Thyroid - Papillary Thyroid CaInfiltrating Duct Carcinoma Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Colon - Mucinous Adenocarcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Metaplastic Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Contra Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cervix Uteri - Carcinoma In-Situ 1 0 1Lobular Carcinoma In Situ Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Therapy-Related AML HL - Nodular Sclerosis 1 1 0Refractory Anemia Acute Myeloid Leukemia 1 1 0
SOFT TISSUE 2 1 1Dermatofibrosarcoma* Skin - Basal Cell Carcinoma 1 1 0
Skin- Squamaous Cell Ca 1 0 1Round Cell Liposarcoma Thyroid - Papillary Carcinoma
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
SKIN 6 3 3Basal Cell Carcinoma Nodular Skin - Basal Cell Carcinoma 1 1 0Basal Cell Carcinoma Skin Lt Temple - Malignant Melanoma 1 0 1Basal Cell Car Nodular*** Skin - Basal Cell Carcinoma 1 0 1
Cheek-Basal Cell CarcinomaSkin Nose - Basal Cell CarcinomaBreast - Malignant phyllodes Tumor
Basal Cell Ca Nodular Skin Scalp/Neck - Basal Cell Carcinoma, 1 0 1Basal Cell Adenocarcinoma** Skin, Lt Nose - Basal Cell Carcinoma 1 1 0
Skin Contra Cheek - Basal Cell CarcinomaSkin: Supraclav Area - Basal Cell Ca
Basal Cell Adenocarcinoma* Skin - Mycosis Fugioides 1 1 0Malignant Lymhpoma Large B-Cell
BRAIN 1 1 0Gliosarcoma Brain - Medulloblastoma 1 1 0
BREAST 48 0 48Lobular Carcinoma Cont Breast - Ductal Ca 1 0 1Intraductal Carcinoma Breast - DCIS 1 0 1Lobular Carcinoma Cont Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Mixed Ca Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Rt Breast - Infiltrating Ductal Ca 1 0 1Lobular Carcinoma Bone Marrow - AML 1 0 1Infiltrating Duct Carcinoma* Tongue - SCC 1 0 1
Cont Breast - Ductal CarcinomaInfiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma In Situ 1 0 1Intraductal Carcinoma Noninfilt Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Intraductal Papillary 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Contra Breast - Ductal Carcinoma
Thyroid - Papillary Thyroid CaInfiltrating Duct Carcinoma Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Colon - Mucinous Adenocarcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Metaplastic Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Contra Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cervix Uteri - Carcinoma In-Situ 1 0 1Lobular Carcinoma In Situ Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Intraductal Carcinoma Noninfil Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Endometrium - Endometrioid Ca 1 0 1
Contral Breast - Ductal CaInfiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct And Lobular Contra Breast - Ductal Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Ovary - Malignant Teratoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma Mixed Ca 1 0 1Infiltrating Duct Carcinoma Thyroid - Papillary Microcarcinoma 1 0 1Lobular Carcinoma Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast -Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Ca 1 0 1Infiltrating Duct Carcinoma Colon Sigmoid - Colonic Adenocarcinoma 1 0 1
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
CORPUS UTERI 10 0 10Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Rt Ovary - Papillary Serous Cystic Tumor 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Carcinoma Breast - Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Adenocarcinoma 1 0 1Squamous Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Thyroid - Papillary Carcinoma 1 0 1Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Endometrioid Carcinoma 1 0 1
OVARY 7 0 7Papillary Cystadenocarcinoma Nos Thyroid - Papillary Adenocarcinoma 1 0 1Mullerian Mixed Tumor Breast - Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Contralateral Ovary - Clear Cell Ca 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Contra Ovary-Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1
CERVIX UTERI / UTERUS 3 0 3Squamous Cell Carcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Squamous Cell Carcinoma Sigmoid Colon - Adenocarcinoma 1 0 1Leiomyosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
VAGINA 1 0 1Squamous Cell Carcinoma Tongue - Microinvasive SCC 1 0 1
PROSTATE GLAND 4 4 0Adenocarcinoma Pancreas - Adenocarcinoma 1 1 0
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
40
Therapy-Related AML HL - Nodular Sclerosis 1 1 0Refractory Anemia Acute Myeloid Leukemia 1 1 0
SOFT TISSUE 2 1 1Dermatofibrosarcoma* Skin - Basal Cell Carcinoma 1 1 0
Skin- Squamaous Cell Ca 1 0 1Round Cell Liposarcoma Thyroid - Papillary Carcinoma
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
SKIN 6 3 3Basal Cell Carcinoma Nodular Skin - Basal Cell Carcinoma 1 1 0Basal Cell Carcinoma Skin Lt Temple - Malignant Melanoma 1 0 1Basal Cell Car Nodular*** Skin - Basal Cell Carcinoma 1 0 1
Cheek-Basal Cell CarcinomaSkin Nose - Basal Cell CarcinomaBreast - Malignant phyllodes Tumor
Basal Cell Ca Nodular Skin Scalp/Neck - Basal Cell Carcinoma, 1 0 1Basal Cell Adenocarcinoma** Skin, Lt Nose - Basal Cell Carcinoma 1 1 0
Skin Contra Cheek - Basal Cell CarcinomaSkin: Supraclav Area - Basal Cell Ca
Basal Cell Adenocarcinoma* Skin - Mycosis Fugioides 1 1 0Malignant Lymhpoma Large B-Cell
BRAIN 1 1 0Gliosarcoma Brain - Medulloblastoma 1 1 0
BREAST 48 0 48Lobular Carcinoma Cont Breast - Ductal Ca 1 0 1Intraductal Carcinoma Breast - DCIS 1 0 1Lobular Carcinoma Cont Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Mixed Ca Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Rt Breast - Infiltrating Ductal Ca 1 0 1Lobular Carcinoma Bone Marrow - AML 1 0 1Infiltrating Duct Carcinoma* Tongue - SCC 1 0 1
Cont Breast - Ductal CarcinomaInfiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma In Situ 1 0 1Intraductal Carcinoma Noninfilt Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cont Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Intraductal Papillary 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Contra Breast - Ductal Carcinoma
Thyroid - Papillary Thyroid CaInfiltrating Duct Carcinoma Contra Breast - Infiltrating Ductal Ca 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Colon - Mucinous Adenocarcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Metaplastic Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Contra Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Cervix Uteri - Carcinoma In-Situ 1 0 1Lobular Carcinoma In Situ Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Intraductal Carcinoma Noninfil Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Endometrium - Endometrioid Ca 1 0 1
Contral Breast - Ductal CaInfiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct And Lobular Contra Breast - Ductal Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Ovary - Malignant Teratoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma Mixed Ca 1 0 1Infiltrating Duct Carcinoma Thyroid - Papillary Microcarcinoma 1 0 1Lobular Carcinoma Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast -Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Ca 1 0 1Infiltrating Duct Carcinoma Colon Sigmoid - Colonic Adenocarcinoma 1 0 1
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
CORPUS UTERI 10 0 10Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Rt Ovary - Papillary Serous Cystic Tumor 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Carcinoma Breast - Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Adenocarcinoma 1 0 1Squamous Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Thyroid - Papillary Carcinoma 1 0 1Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Endometrioid Carcinoma 1 0 1
OVARY 7 0 7Papillary Cystadenocarcinoma Nos Thyroid - Papillary Adenocarcinoma 1 0 1Mullerian Mixed Tumor Breast - Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Contralateral Ovary - Clear Cell Ca 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Contra Ovary-Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1
CERVIX UTERI / UTERUS 3 0 3Squamous Cell Carcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Squamous Cell Carcinoma Sigmoid Colon - Adenocarcinoma 1 0 1Leiomyosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
VAGINA 1 0 1Squamous Cell Carcinoma Tongue - Microinvasive SCC 1 0 1
PROSTATE GLAND 4 4 0Adenocarcinoma Pancreas - Adenocarcinoma 1 1 0
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Intraductal Carcinoma Noninfil Contralateral Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma* Endometrium - Endometrioid Ca 1 0 1
Contral Breast - Ductal CaInfiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Endometrium - Endometrioid 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Lobular Carcinoma Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Breast - DCIS 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct And Lobular Contra Breast - Ductal Carcinoma 1 0 1Intraductal Carcinoma Noninfiltrating Ovary - Malignant Teratoma 1 0 1Infiltrating Duct Carcinoma Breast - Ductal Carcinoma Mixed Ca 1 0 1Infiltrating Duct Carcinoma Thyroid - Papillary Microcarcinoma 1 0 1Lobular Carcinoma Contra Breast - Lobular Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast - Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contra Breast -Ductal Carcinoma 1 0 1Infiltrating Duct Carcinoma Contralateral Breast - Ductal Ca 1 0 1Infiltrating Duct Carcinoma Colon Sigmoid - Colonic Adenocarcinoma 1 0 1
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
CORPUS UTERI 10 0 10Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Rt Ovary - Papillary Serous Cystic Tumor 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Carcinoma Breast - Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Adenocarcinoma 1 0 1Squamous Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 0 1Endometrioid Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Thyroid - Papillary Carcinoma 1 0 1Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Endometrioid Adenocarcinoma Ovary - Endometrioid Carcinoma 1 0 1
OVARY 7 0 7Papillary Cystadenocarcinoma Nos Thyroid - Papillary Adenocarcinoma 1 0 1Mullerian Mixed Tumor Breast - Ductal Carcinoma 1 0 1Clear Cell Adenocarcinoma Contralateral Ovary - Clear Cell Ca 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Contra Ovary-Serous Cyst Adenoca 1 0 1Serous Cystadenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Serous Cystadenocarcinoma Contra Ovary - Serous Cyst Adenoca 1 0 1
CERVIX UTERI / UTERUS 3 0 3Squamous Cell Carcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Squamous Cell Carcinoma Sigmoid Colon - Adenocarcinoma 1 0 1Leiomyosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
VAGINA 1 0 1Squamous Cell Carcinoma Tongue - Microinvasive SCC 1 0 1
PROSTATE GLAND 4 4 0Adenocarcinoma Pancreas - Adenocarcinoma 1 1 0
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Rectum - Adenocarcinoma 1 1 0
Colon - Mucinous AdenocarcinomaAdenocarcinoma HL - Nodular Sclerosis 1 1 0
Sigmoid Colon - Mucinous Adenoca
TESTIS 1 1 0Hemangiosarcoma Testis - Embryonal Carcinoma 1 1 0
KIDNEY 4 2 2Renal Cell Carcinoma Nos Thyroid - Papillary Ca 1 1 0Papillary Transitional Cell Ca Bladder - Papillary Urothelial Ca 1 0 1Renal Cell Carcinoma Nos Contralateral Kidney - Renal Cell Ca 1 0 1Renal Cell Carcinoma Chromophobe Kidney - Chromophobe Renal Cell Ca 1 1 0
URINARY BLADDER 10 9 1Squamous Cell Carcinoma Pancreas - Adenocarcinoma 1 0 1Papillary Transitional Cell Ca Non Hodgkin's Lymphoma 1 1 0Papillary Transitional Cell Ca Ureteral Orifice - Papillary Urothelial Ca 1 1 0Papillary Transitional Cell Carcinoma Bladder -Urothelial Carcinoma In Situ 1 1 0Papillary Transitional Cell Ca Prostate - Prostatic Adenocarcinoma 1 1 0Papillary Transitional Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 1 0Papillary Transitional Cell Ca Parotid - Warthin Tumor 1 1 0Papillary Transitional Cell Carcinoma Rectum - Adenocarcinoma 1 1 0Papillary Transitional Cell Ca Unknown Primary - Carcinoma 1 1 0Papillary Transitional Cell Carcinoma Bladder - Invasive Carcinoma 1 1 0
ESOPHAGUS 4 1 3Adenocarcinoma Kidney - Renal Cell Carcinoma 1 0 1Squamous Cell Carcinoma Stomach - GIST 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Undifferentiated NHL 1 0 1
LYMPH NODES 7 4 3Non-Hodgkin's Lymphoma Prostate - Adenocarcinoma 1 1 0Non-Hodgkin's Lymphoma HL, Mixed Cellularity 1 1 0Non-Hodgkin's Lymphoma Breast - Ductal Carcinoma 1 0 1Non-Hodgkin's Lymphoma Skin - Kaposi's Sarcoma 1 0 1Non-Hodgkin's Lymphoma Bone Marrow - MDS 1 1 0Non-Hodgkin's Lymphoma Liver - Hepatocellular Carcinoma 1 1 0Non-Hodgkin's Lymphoma Thyroid - Papillary Carcinoma 1 0 1
THYROID 10 2 8Papillary Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Follicular Carcinoma Thyroid - Papillary Microcarcinoma 1 0 1Papillary Adenocarcinoma Colon - Mucinous Adenocarcinoma 1 0 1Papillary Microcarcinoma Kidney - Renal Cell Carcinoma 1 1 0Follicular Adenocarcinoma Skin - Basal Cell Carcinoma 1 1 0Papillary Carcinoma Encapsulated Thyroid - Marginal Zone B-Cell Lymphoma 1 0 1Papillary Carcinoma Endometrium - Endometrioid 1 0 1Papillary Adenocarcinoma Maxillary Bone - Osteosarcoma 1 0 1Papillary Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Oxyphilic Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1
UNKNOWN PRIMARY 2 0 2Adenocarcinoma Liver - Hepatocellular Carcinoma 1 0 1Adenocarcinoma Liver - Hepatocellular Carcinoma 1 0 1
41
Lymphoma Large B-cell Prostate - Adenocarcinoma 1 1 0
SMALL INTESTINE 3 2 1Adenocarcinoma Rectum - Mucinous Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
COLON 5 4 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Neoplasm Malignant Small Instestine - Adenocarcinoma 1 1 0Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Adenocarcinoma Stomach - Adenocarcinoma 1 1 0
PRIMARY SITE HISTOLOGY OTHER PRIMARIES ALL CASES MALE FEMALE
RECTOSIGMOID JUNCTION 9 6 3Adenocarcinoma GI Tract - GIST 1 1 0Adenocarcinoma Breast - Lobular Carcinoma 1 0 1Adenocarcinoma Rectosigmoid - Adenocarcinoma 1 1 0Adenocarcinoma Gum - SCC 1 0 1Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Liver - Hepatocellular Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Prostate - Prostatic Adenocarcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 0 1
ANUS/ANAL CANAL 1 0 1Squamous Cell Carcinoma Thyroid - Follicular Carcinoma 1 0 1
LIVER, INTRAHEPATIC BILE DUCT 3 2 1Hepatocellular Carcinoma Stomach - DLBCL 1 0 1Hepatoblastoma Bone Marrow - AML 1 1 0Hepatocellular Carcinoma Prostate - Adenocarcinoma 1 1 0
PANCREAS / AMPULLA OF VATER 2 1 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Vulva - Squamous Cell Carcinoma 1 0 1
LUNG 6 4 2Adenocarcinoma Thyroid - Papillary Adenocarcinoma 1 0 1Squamous Cell Carcinoma Nasopharynx - Carcinoma 1 1 0Adenocarcinoma Colon - Adenocarcinoma 1 1 0Mucinous Adenocarcinoma Cervix uteri - Squamous Cell In Situ 1 0 1Squamous Cell Carcinoma Tongue - SCC 1 1 0Adenocarcinoma Bladder - Papillary Transitional Cell 1 1 0
BONE 1 0 1Chondroblastic Osteosarcoma Thyroid - Papillary Microcarcinoma 1 0 1
BONE MARROW 6 4 2Acute Myelomonocytic Leukemia Bone marrow - CML 1 1 0Acute Myelomonocytic Leukemia* Thyroid - Medullary Carcinoma 1 0 1Therapy-Related AML** Soft Tissue - Embryonal 1 1 0
Bone - OsteosarcomaAcute Myeloid Leukemia Nos Periph Nerves - Ganglioneuroblastoma 1 0 1
2014 (NOS - Not Otherwise Specified) (PREVIOUS OR CONCURRENT)
Adenocarcinoma Colon - Adenocarcinoma 1 1 0Adenocarcinoma Rectum - Adenocarcinoma 1 1 0
Colon - Mucinous AdenocarcinomaAdenocarcinoma HL - Nodular Sclerosis 1 1 0
Sigmoid Colon - Mucinous Adenoca
TESTIS 1 1 0Hemangiosarcoma Testis - Embryonal Carcinoma 1 1 0
KIDNEY 4 2 2Renal Cell Carcinoma Nos Thyroid - Papillary Ca 1 1 0Papillary Transitional Cell Ca Bladder - Papillary Urothelial Ca 1 0 1Renal Cell Carcinoma Nos Contralateral Kidney - Renal Cell Ca 1 0 1Renal Cell Carcinoma Chromophobe Kidney - Chromophobe Renal Cell Ca 1 1 0
URINARY BLADDER 10 9 1Squamous Cell Carcinoma Pancreas - Adenocarcinoma 1 0 1Papillary Transitional Cell Ca Non Hodgkin's Lymphoma 1 1 0Papillary Transitional Cell Ca Ureteral Orifice - Papillary Urothelial Ca 1 1 0Papillary Transitional Cell Carcinoma Bladder -Urothelial Carcinoma In Situ 1 1 0Papillary Transitional Cell Ca Prostate - Prostatic Adenocarcinoma 1 1 0Papillary Transitional Cell Carcinoma Thyroid - Papillary Thyroid Carcinoma 1 1 0Papillary Transitional Cell Ca Parotid - Warthin Tumor 1 1 0Papillary Transitional Cell Carcinoma Rectum - Adenocarcinoma 1 1 0Papillary Transitional Cell Ca Unknown Primary - Carcinoma 1 1 0Papillary Transitional Cell Carcinoma Bladder - Invasive Carcinoma 1 1 0
ESOPHAGUS 4 1 3Adenocarcinoma Kidney - Renal Cell Carcinoma 1 0 1Squamous Cell Carcinoma Stomach - GIST 1 0 1Adenocarcinoma Rectum - Adenocarcinoma 1 1 0Carcinoma Undifferentiated NHL 1 0 1
LYMPH NODES 7 4 3Non-Hodgkin's Lymphoma Prostate - Adenocarcinoma 1 1 0Non-Hodgkin's Lymphoma HL, Mixed Cellularity 1 1 0Non-Hodgkin's Lymphoma Breast - Ductal Carcinoma 1 0 1Non-Hodgkin's Lymphoma Skin - Kaposi's Sarcoma 1 0 1Non-Hodgkin's Lymphoma Bone Marrow - MDS 1 1 0Non-Hodgkin's Lymphoma Liver - Hepatocellular Carcinoma 1 1 0Non-Hodgkin's Lymphoma Thyroid - Papillary Carcinoma 1 0 1
THYROID 10 2 8Papillary Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Follicular Carcinoma Thyroid - Papillary Microcarcinoma 1 0 1Papillary Adenocarcinoma Colon - Mucinous Adenocarcinoma 1 0 1Papillary Microcarcinoma Kidney - Renal Cell Carcinoma 1 1 0Follicular Adenocarcinoma Skin - Basal Cell Carcinoma 1 1 0Papillary Carcinoma Encapsulated Thyroid - Marginal Zone B-Cell Lymphoma 1 0 1Papillary Carcinoma Endometrium - Endometrioid 1 0 1Papillary Adenocarcinoma Maxillary Bone - Osteosarcoma 1 0 1Papillary Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1Oxyphilic Adenocarcinoma Breast - Infiltrating Ductal Carcinoma 1 0 1
UNKNOWN PRIMARY 2 0 2Adenocarcinoma Liver - Hepatocellular Carcinoma 1 0 1Adenocarcinoma Liver - Hepatocellular Carcinoma 1 0 1
* Patient has three primary malignancies** Patient has four primary malignancies*** Patient has five primary malignancies
4242
STAGE OF DISEASE AT DIAGNOSIS Stage in any malignant process may be defined as the particular step, phase, or extent in a tumor's development, which is one of the predictors for outcome and treatment selection assigned at the time of initial diagnosis. The microscopic appearance, extent, and biological behavior of a tumor, as well as host factors, play a part in prognosis and are therefore important in staging. The SEER (Surveillance, Epidemiology and End Results) Summary Staging Guide was utilized for all stage-able cases. This system summarizes the disease categories into four general staging groups (i.e., in situ, localized, regional and distant). Stage categories are based on a combination of clinical observations and operative-pathological evaluation. Summary Staging Definitions: IN SITU : Intraepithelial, noninvasive, non-infiltrating LOCALIZED : Within organ a. Invasive cancer confined to the organ of origin b. Intraluminal extension where specified REGIONAL : Beyond the organ of origin a. By direct extension to adjacent organs/tissues b. To regional lymph nodes c. Both (a) and (b) DISTANT : Direct extension or metastasis a. Direct continuity to organs other than above b. Discontinuous metastasis c. To distant lymph nodes Systemic diseases, i.e., leukemia and multiple myeloma and cases of unstageable unknown primary were disregarded in graphically illustrating the stages for all analytic cases seen at KFSH&RC in 2014 (Figure 13). The 37 cases unstageable at diagnosis were those patients who refused further diagnostic workup, or further workup was not possible due to the patients' state of health, e.g., terminal cases or those with co-morbid conditions, or those with not enough information from the referring hospitals to stage the disease. Please refer also to Table 5 for the distribution of the 2014 analytic cases by site and stage at diagnosis. In addition to the SEER Summary Staging, the cases were also staged according to the American Joint Committee on Cancer (AJCC) TNM system. This scheme is based on the premise that cancers of similar histology or site of origin share similar patterns of growth and extension. This system is based on the assessment of three components: T: Extent of the primary tumor N: Absence or presence and extent of regional lymph node involvement M: Absence or presence of distant metastasis Analytic cases of six major sites, i.e., breast, lung, nasopharynx, stomach, colorectal, and hodgkin’s lymphoma are presented in Table 12 with their clinical group stages and yearly comparative figures from 2009 to 2014.
43
SURG&RAD&CHEMO30(1.2%)
RADIATION395(15.5%)
SURGERY409(16.1%)
FIGURE14
DISTRIBUTIONOFANALYTICCASESBYFIRSTCOURSEOFTREATMENTMODALITY
2014(TOTALCASES=2,543)
RAD&CHEMO591(23.2%)
SURG&CHEMO6(10.2%)
NOTREATMENT141(5%)
CHEMOTHERAPY427(16.8%)
SURG&RAD591(23.2%)
INSITU48(2.1%)
DISTANT*632(27.5%)
FIGURE13
DISTRIBUTIONOFANALYTICCASESBYSTAGE(SEER)ATDIAGNOSIS2014(TOTALCASES=2,301)
*ExcludesHematopoie2cPrimaries(220cases)**ExcludesUnstageableUnknownPrimaries(1case)
UNSTAGEABLE**37(1.6%)
LOCALIZED777(33.8%)
REGIONAL 807(35.1%)
FIGURE 14
DISTRIBUTION OF ANALYTIC CASES BYFIRST COURSE OF TREATMENT MODALITY
2014 (TOTAL CASES = 2,543)
FIGURE 13
DISTRIBUTION OF ANALYTIC CASESBY STAGE (SEER) AT DIAGNOSIS
2014 (TOTAL CASES = 2,301)
REGIONAL 807 (35.1%)
DISTANT* 632 (27.5 %)
CHEMOTHERAPY 427 (16.8%)
SURGERY 409 (16.1%)
NO TREATMENT 141 (5%)
RAD & CHEMO 591 (23.2%) SURG & CHEMO 6 (10.2%)
SURG & RAD 591 (23.2%)
RADIATION 395 (15.5%)
SURG & RAD & CHEMO 30 (1.2%)
UNSTAGEABLE** 37 (1.6%)
LOCALIZED 777 (33.8%)
IN SITU 48 (2.1 %)
*Excludes Hematopoietic Primaries (220 cases) **Excludes Unstageable Unknown Primaries (1 case)
44
BREASTStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 6 1.7 12 3.1 13 3.7 13 3.3 14 3.2 58 3.11 - - - - - - 6 1.5 33 7.5 40 2.21A 37 10.6 39 10.2 37 10.5 26 6.5 9 2.1 139 7.71B 0 0.0 0 0.0 0 0.0 2 0.5 0 0.0 2 0.12A 61 17.5 66 17.2 71 20.0 81 20.3 69 15.8 348 18.02B 51 14.7 60 15.6 33 9.3 60 15.0 81 18.5 285 13.83A 16 4.6 30 7.8 31 8.7 45 11.3 49 11.2 171 7.73B 34 9.8 44 11.4 39 11.0 50 12.5 61 14.0 228 11.33C 5 1.4 3 0.8 8 2.3 1 0.3 9 2.1 26 1.24 71 20.4 64 16.7 63 17.8 64 16.0 92 21.1 354 18.5Unstageable 67 19.3 66 17.2 59 16.7 51 12.8 20 4.5 263 16.4
Total 348 100.0 384 100.0 354 100.0 399 100.0 437 100.0 1,922 100.0
LUNGStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.01A 4 6.7 4 5.9 5 7.6 3 4.2 2 2.4 18 6.01B 0 0.0 4 5.9 2 3.0 3 4.2 1 1.2 10 4.72A 0 0.0 2 2.9 3 4.5 3 4.2 0 0 8 2.52B 3 5.0 0 0.0 0 0.0 2 2.8 1 1.2 6 2.23A 7 11.7 5 7.4 5 7.6 5 7.0 8 10 30 7.83B 3 5.0 7 10.3 5 7.6 7 9.9 3 3.7 25 9.74 43 71.7 41 60.2 39 59.1 43 60.7 26 31.7 192 60.8Unstageable 0 0.0 5 7.4 7 10.6 5 7.0 41 50 58 6.3
Total 60 100.0 68 100.0 66 100.0 71 100.0 82 100.0 347 100.0
NASOPHARYNXStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.01 2 2.8 4 6.3 2 3.6 4 6.2 1 1.9 13 4.22 6 8.5 8 12.7 5 9.1 1 1.5 4 7.4 20 6.52A - - - - - - - - - - 1 0.32B - - - - - - - - - - 2 0.63 19 26.8 13 20.6 9 16.4 10 15.4 8 14.8 72 23.34A 13 18.3 12 19.0 17 30.9 15 23.1 14 25.9 66 21.44B 21 29.6 18 28.6 17 30.9 24 36.9 13 24.1 93 30.14C 9 12.7 8 12.7 4 7.3 11 16.9 3 5.6 39 12.6Unstageable 1 1.4 0 0.0 1 1.8 0 0.0 11 20.4 3 1.0
Total 71 100.0 63 100.0 55 100.0 65 100.0 54 100.0 309 100.0
* Excludes Lymphoma Cases 44
TABLE 12
AJCC CLINICAL TNM GROUP STAGE OF ANALYTIC CASES OF MAJOR SITES* BY YEAR 2009 - 2014
BREAST Stage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 6 1.7 12 3.1 13 3.7 13 3.3 14 3.2 58 3.1 1 - - - - - - 6 1.5 33 7.5 40 2.2 1A 37 10.6 39 10.2 37 10.5 26 6.5 9 2.1 139 7.7 1B 0 0.0 0 0.0 0 0.0 2 0.5 0 0.0 2 0.1 2A 61 17.5 66 17.2 71 20.0 81 20.3 69 15.8 348 18.0 2B 51 14.7 60 15.6 33 9.3 60 15.0 81 18.5 285 13.8 3A 16 4.6 30 7.8 31 8.7 45 11.3 49 11.2 171 7.7 3B 34 9.8 44 11.4 39 11.0 50 12.5 61 14.0 228 11.3 3C 5 1.4 3 0.8 8 2.3 1 0.3 9 2.1 26 1.2 4 71 20.4 64 16.7 63 17.8 64 16.0 92 21.1 354 18.5 Unstageable 67 19.3 66 17.2 59 16.7 51 12.8 20 4.5 263 16.4 Total 348 100.0 384 100.0 354 100.0 399 100.0 437 100.0 1,922 100.0
NASOPHARYNX Stage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No % 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2 2.8 4 6.3 2 3.6 4 6.2 1 1.9 13 4.2 2 6 8.5 8 12.7 5 9.1 1 1.5 4 7.4 20 6.5 2A - - - - - - - - - - 1 0.3 2B - - - - - - - - - - 2 0.6 3 19 26.8 13 20.6 9 16.4 10 15.4 8 14.8 72 23.3 4A 13 18.3 12 19.0 17 30.9 15 23.1 14 25.9 66 21.4 4B 21 29.6 18 28.6 17 30.9 24 36.9 13 24.1 93 30.1 4C 9 12.7 8 12.7 4 7.3 11 16.9 3 5.6 39 12.6 Unstageable 1 1.4 0 0.0 1 1.8 0 0.0 11 20.4 3 1.0 Total 71 100.0 63 100.0 55 100.0 65 100.0 54 100.0 309 100.0
LUNG Stage 2010 2011 2012 2013 2014 T O T A L No % No % No % No % No % No % 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1A 4 6.7 4 5.9 5 7.6 3 4.2 2 2.4 18 6.0 1B 0 0.0 4 5.9 2 3.0 3 4.2 1 1.2 10 4.7 2A 0 0.0 2 2.9 3 4.5 3 4.2 0 0 8 2.5 2B 3 5.0 0 0.0 0 0.0 2 2.8 1 1.2 6 2.2 3A 7 11.7 5 7.4 5 7.6 5 7.0 8 10 30 7.8 3B 3 5.0 7 10.3 5 7.6 7 9.9 3 3.7 25 9.7 4 43 71.7 41 60.2 39 59.1 43 60.7 26 31.7 192 60.8 Unstageable 0 0.0 5 7.4 7 10.6 5 7.0 41 50 58 6.3 Total 60 100.0 68 100.0 66 100.0 71 100.0 82 100.0 347 100.0
45
AJCC CLINICAL TNM GROUP STAGE OF ANALYTIC* CASES OF MAJOR SITES BY YEAR2009 - 2014
HODGKIN'S LYMPHOMAStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
1A 4 4.8 3 4.3 8 9.2 7 8.2 13 10.6 35 6.11B 1 1.2 0 0.0 0 0.0 1 1.2 1 0.8 3 1.02A 22 26.5 17 24.3 19 21.8 14 16.5 28 21.9 100 22.42B 10 12.0 5 7.1 8 9.2 10 11.8 14 10.9 47 10.03A 8 9.6 10 14.3 15 17.2 16 18.8 19 14.8 68 16.53B 11 13.3 12 17.1 6 6.9 11 12.9 12 9.4 52 11.74A 2 2.4 5 7.1 9 10.3 7 8.2 7 5.5 30 7.94B 24 29.0 18 25.7 21 24.1 19 22.3 26 20.3 108 23.7Unstageable 1 1.2 0 0.0 1 1.1 0 0.0 8 6.3 10 0.7
Total 83 100.0 70 100.0 87 100.0 85 100.0 128 100.0 453 100.0
STOMACHStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 0 0.0 0 0.0 0 0.0 2 3.5 0 0.0 2 0.71A 0 0.0 1 1.9 0 0.0 1 1.8 2 1.8 4 0.71B 4 7.1 2 3.7 0 0.0 0 0.0 1 1.9 7 3.22 - - - - - - - - - - 5 1.82A 2 3.6 2 3.7 1 1.9 0 0.0 1 1.9 5 1.82B 1 1.8 2 3.7 2 3.7 0 0.0 0 0.0 5 1.83A 3 5.4 1 1.8 1 1.9 1 1.8 0 0.0 6 2.53B 5 8.9 2 3.7 1 1.9 1 1.8 1 1.8 10 4.73C 3 5 5 9.3 0 0.0 0 0.0 0 0.0 8 2.94 5 8.9 2 3.7 2 3.7 2 3.5 9 3.5 20 6.8Unstageable 33 58.9 37 68.5 47 87.0 50 87.7 46 87.7 213 73.1
Total 56 100.0 54 100.0 54 100.0 57 100.0 60 100.0 285 100.0
COLON, RECTUMStage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 1 0.11 6 4.1 10 5.8 7 4.2 6 3.4 2 2.2 31 4.72A 12 8.2 16 9.3 10 5.9 24 13.5 2 2.2 64 9.72B 1 0.7 0 0.0 1 0.6 4 2.3 0 0.0 6 0.82C 2 1.4 0 0.0 1 0.6 0 0.0 0 0.0 3 0.43A 2 1.4 3 1.7 2 1.2 1 0.6 1 1.1 9 1.23B 7 4.8 17 9.9 20 12.0 12 6.8 3 3.3 59 8.53C 4 2.7 2 1.2 4 2.4 9 5.0 2 2.2 21 2.84 - - - - 1 0.6 0 0.0 0 0.0 18 2.24A 10 6.8 8 4.7 6 3.6 15 8.5 5 5.4 40 4.84B 12 8.2 7 4.1 6 3.6 7 4.0 1 1.1 32 3.94C 0 0.0 0 0.0 2 1.2 0 0.0 1 1.1 2 0.2Unstageable 90 61.6 109 63.3 106 63.5 99 55.9 75 81.5 479 60.7
Total 146 100.0 172 100.0 167 100.0 177 100.0 92 100.1 765 100.044
TABLE 12
AJCC CLINICAL TNM GROUP STAGE OF ANALYTIC CASES OF MAJOR SITES* BY YEAR 2009 - 2014
BREAST Stage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No %
0 6 1.7 12 3.1 13 3.7 13 3.3 14 3.2 58 3.1 1 - - - - - - 6 1.5 33 7.5 40 2.2 1A 37 10.6 39 10.2 37 10.5 26 6.5 9 2.1 139 7.7 1B 0 0.0 0 0.0 0 0.0 2 0.5 0 0.0 2 0.1 2A 61 17.5 66 17.2 71 20.0 81 20.3 69 15.8 348 18.0 2B 51 14.7 60 15.6 33 9.3 60 15.0 81 18.5 285 13.8 3A 16 4.6 30 7.8 31 8.7 45 11.3 49 11.2 171 7.7 3B 34 9.8 44 11.4 39 11.0 50 12.5 61 14.0 228 11.3 3C 5 1.4 3 0.8 8 2.3 1 0.3 9 2.1 26 1.2 4 71 20.4 64 16.7 63 17.8 64 16.0 92 21.1 354 18.5 Unstageable 67 19.3 66 17.2 59 16.7 51 12.8 20 4.5 263 16.4 Total 348 100.0 384 100.0 354 100.0 399 100.0 437 100.0 1,922 100.0
NASOPHARYNX Stage 2010 2011 2012 2013 2014 T O T A L
No % No % No % No % No % No % 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2 2.8 4 6.3 2 3.6 4 6.2 1 1.9 13 4.2 2 6 8.5 8 12.7 5 9.1 1 1.5 4 7.4 20 6.5 2A - - - - - - - - - - 1 0.3 2B - - - - - - - - - - 2 0.6 3 19 26.8 13 20.6 9 16.4 10 15.4 8 14.8 72 23.3 4A 13 18.3 12 19.0 17 30.9 15 23.1 14 25.9 66 21.4 4B 21 29.6 18 28.6 17 30.9 24 36.9 13 24.1 93 30.1 4C 9 12.7 8 12.7 4 7.3 11 16.9 3 5.6 39 12.6 Unstageable 1 1.4 0 0.0 1 1.8 0 0.0 11 20.4 3 1.0 Total 71 100.0 63 100.0 55 100.0 65 100.0 54 100.0 309 100.0
LUNG Stage 2010 2011 2012 2013 2014 T O T A L No % No % No % No % No % No % 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1A 4 6.7 4 5.9 5 7.6 3 4.2 2 2.4 18 6.0 1B 0 0.0 4 5.9 2 3.0 3 4.2 1 1.2 10 4.7 2A 0 0.0 2 2.9 3 4.5 3 4.2 0 0 8 2.5 2B 3 5.0 0 0.0 0 0.0 2 2.8 1 1.2 6 2.2 3A 7 11.7 5 7.4 5 7.6 5 7.0 8 10 30 7.8 3B 3 5.0 7 10.3 5 7.6 7 9.9 3 3.7 25 9.7 4 43 71.7 41 60.2 39 59.1 43 60.7 26 31.7 192 60.8 Unstageable 0 0.0 5 7.4 7 10.6 5 7.0 41 50 58 6.3 Total 60 100.0 68 100.0 66 100.0 71 100.0 82 100.0 347 100.0
46
IV. SPECIAL STUDY
RENAL CARCINOMA; KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER EXPERIENCE
Fazal Hussain, MD, Shouki Bazarbashi, MD, Naeem Chaudhri, MD
Renal carcinoma is the 10th most common cancer among men and 14th most common cancer among women at KFSH&RC. During the year 2014, an ascending trend with 95 new cases of renal carcinoma was reported at KFSHRC as compared to 77 cases in 2013. Out of these new cases, 80 cases were analytical; 48 males and 32 females. KFSH&RC is the tertiary care referral center and have seen a steady increase in the numbers of renal carcinoma cases since 1975 (Figure 1). It’s primarily due to significant expansion of cancer services, including screening and early detection, in the Kingdom and partly due to incidental diagnoses during abdominal imaging. A total of 1,970 renal cancer cases have been registered at KFSH&RC out of a total of 80,978 cancer cases by the end of 2014. Renal cancers accounts for 2.4% of all cancers seen at KFSH&RC; 4.6% of all male and 2.1% of all female malignant cases with a male to female ratio of 2.2:1. Men are twice as likely as women to be diagnosed with renal cancer.
FIGURE 1 DISTRIBUTION OF RENAL CANCER CASES (1975-2014)
Relative frequencies of major cancers seen at KFSH&RC although reflect the national trends as evidenced by Saudi Cancer Registry data, are very different from the Western countries. For instance, renal carcinomas including renal pelvis accounts for 2.4% of all cancer cases at our center, 2.6% in Saudi Cancer Registry, and 4% of all cancers in the United States. Majority (32%) of our renal cancer patients are referred from the Central Region (Riyadh). Although our center receives patients from all parts of the Kingdom; Hail, Qassim, Asir, and Eastern Province are the major referring areas for renal cancers to KFSH&RC (Figure 2). Table 1. Distribution of renal cancer by stage during 2014.
TNM Cl Stage I II III IV Unk Number of cases 12 9 2 10 62
050
100150200250300350400450
1975-1979 1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2009 2010-2014
MALE FEMALE
47
Table 2. Distribution of renal cancer by grade during 2014.
Grade I II III Undifferentiated Unk Number of cases 1 26 10 10 48
FIGURE 2 DISTRIBUTION OF 2014 RENAL CANCER ANALYTIC CASES BY REGION
(BASED ON GIVEN ADDRESS AT THE TIME OF DIAGNOSIS)
Majority of these renal cancer patients present in 50-69 years of age group. However, the age distribution is bimodal with majority presenting in <20 years of age group and during the 5th-6th decades of life (Figure 3).
FIGURE 3
DISTRIBUTION OF 2014 RENAL CANCER ANALYTIC CASES BY AGE VS. SEX
RIYADH32%
HAIL13%QASSIM
13%
ASIR11%
EP9%
MAKKAH5%
JOUF4%
MADINAH4%
NP4%
JAZAN1%
NP1%
OT1%
SP1%
TABUK1%
0
2
4
6
8
10
12
14
16
18
20
<20 20-29 30-39 40-49 50-59 60-69 70-79 79+
Female
Male
48
Histo-pathologically, majority of renal cancers seen at KFSH&RC were Renal Cell Carcinomas (RCC) and Clear Cell Carcinoma (TCC, also known as Urothelial Cell Carcinoma) of the renal pelvis, followed by Transitional Cell Carcinoma. During 2014, 41.3% of all renal cancers seen at our institution were RCC, 26.2% were Clear Cell Carcinoma and 6.2% were TCC. Only 3.8% were Adenocarcinomas (Figure 4).
FIGURE 4 DISTRIBUTION OF 2014 RENAL CANCER ANALYTIC CASES BY HISTO-PATHOLOGICAL TYPE
As per Saudi Cancer Registry (SCR) 2014 published report, annual incidence rate of Kidney cancer (including renal pelvis) for the Kingdom of Saudi Arabia was 2.6% of all newly diagnosed cases in 2014; A total of 407 cases (268 males and 139 females). It ranked as the 10th most common cancer among males and 13th among females with a M:F ratio of 1.9:1.0. The median age at diagnosis was 56 years among males and 49 years among females in Saudi population. Renal cancer was ranked as the 5th most common cancer among Saudi male pediatric patients and the 4th most common cancer among Saudi female pediatric patients, during 2014, as reported by SCR (Figures 5). Most of the early stage renal cancers presented with no symptoms. With disease advancing stage and disease progression, symptoms included hematuria, pain or mass in lower back or abdomen, fatigue, weight loss, fever, and lower extremity edema.
0
5
10
15
20
25
30
35
49
Figure 5 with permission from Saudi Cancer Registry (SCR) Annual Report, 2014
FIGURE 5 DISTRIBUTION OF PEDIATRIC CANCER CASES (0-14 YEARS) AMONG SAUDI NATIONALS BY
GENDER AND AGE GROUPS, 2014
In the GCC States, renal cancer is the 7th most common cancer among males below 15 years of age and 5th most common cancer among females in this age group between 1998-2009. The overall ASR was 2.5 and 1.6 per 100,000 populations for males and females, respectively. There has been a gradual increase in ASR among males and females from 1998-2009 (Table 3). Renal cancer incidence is significantly higher among males compared to females in all GCC States. The highest incidence of renal cancers is among Kuwaiti men with ASR of 5.3 followed by Bahrain with ASR 0f 4.6. Renal cancer incidence continues to incline over the twelve-year period (1998-2009) in all GCC States. The total number of newly diagnosed renal cancers increased exponentially over the twelve-year period, with significant increase in the ASR trend among males during the same period. Cigarette smoking, obesity, and hypertension are well established as risk factors for RCC and there is some evidence implicating physical inactivity and dietary factors. Recent changes in lifestyle in the Middle East and, to a lesser extent, in North Africa, may have an impact on the incidence of RCC in the future. Increasing obesity rates associated with Westernization of the diet and reduced physical activity are particularly relevant. Table 3. Distribution of renal cancer and Age Standardized Rate (ASR) per 100,000 population All GCC by gender during 1998-2001, 2002-2005, and 2006-2009.
Year Males Females 1998-2001 1.9 1.4 2002-2005 2.3 1.5 2006-2009 2.8 1.6
Figure 5 with permission from Saudi Cancer Registry (SCR) Annual Report, 2014
FIGURE 5 DISTRIBUTION OF PEDIATRIC CANCER CASES (0-14 YEARS) AMONG SAUDI NATIONALS BY
GENDER AND AGE GROUPS, 2014
In the GCC States, renal cancer is the 7th most common cancer among males below 15 years of age and 5th most common cancer among females in this age group between 1998-2009. The overall ASR was 2.5 and 1.6 per 100,000 populations for males and females, respectively. There has been a gradual increase in ASR among males and females from 1998-2009 (Table 3). Renal cancer incidence is significantly higher among males compared to females in all GCC States. The highest incidence of renal cancers is among Kuwaiti men with ASR of 5.3 followed by Bahrain with ASR 0f 4.6. Renal cancer incidence continues to incline over the twelve-year period (1998-2009) in all GCC States. The total number of newly diagnosed renal cancers increased exponentially over the twelve-year period, with significant increase in the ASR trend among males during the same period. Cigarette smoking, obesity, and hypertension are well established as risk factors for RCC and there is some evidence implicating physical inactivity and dietary factors. Recent changes in lifestyle in the Middle East and, to a lesser extent, in North Africa, may have an impact on the incidence of RCC in the future. Increasing obesity rates associated with Westernization of the diet and reduced physical activity are particularly relevant. Table 3. Distribution of renal cancer and Age Standardized Rate (ASR) per 100,000 population All GCC by gender during 1998-2001, 2002-2005, and 2006-2009.
Year Males Females 1998-2001 1.9 1.4 2002-2005 2.3 1.5 2006-2009 2.8 1.6
50
An estimated 337,860 new renal cancer cases occurred worldwide in 2012 and there were 143,406 deaths as a result of it. It is the 9th most common cancer in men (213,924 cases, 2.9% of the total) and the 14th in women (123,936 cases, 1.9%). Men are twice as likely as women to be diagnosed with renal cancer. An estimated 63,990 new renal cancer cases will be diagnosed in the USA and 14,400 deaths will result from it in 2017. In North America and other Western countries, obesity and tobacco smoking are strong risk factors for renal cancers. Hypertension, chronic renal failure, occupational hazards (trichloroethylene), radiation exposure, genetic disorders (von Hippel-Lindau disease, hereditary papillary renal cell carcinoma) are additional risk factors. The overall 5-yr relative survival rate for renal cancer has been reported as 74%. About 66% of the renal malignancies are diagnosed at early (loco-regional) stage with a 5-yr relative survival rate of 93%. Renal cancers at KFSH&RC are managed by multidisciplinary approach by all the oncology services, urology, pathology, radiology, family medicine department and oncology nursing, as appropriate. Surgery is the primary treatment for most of the localized renal cancers. Patient who are not eligible for surgery are considered for local ablative therapy. Adjuvant therapy have only shown benefit with Sunitinib in patients with high risk features. Other TKI’s have failed to show any improvement with adjuvant therapy. Several other trials using other targeted therapies and immunotherapy are ongoing. For metastatic cancers, targeted therapies and immunotherapy using checkpoint inhibitors are the gold standard sometime with cytoreductive nephrectomy at KFSH&RC. In summary, renal cancers remain one of the leading cancers in the Kingdom of Saudi Arabia and form a significant proportion of new patients referred to King Faisal Specialist Hospital & Research Center. Management of renal cancers continues to evolve with significant improvements in therapeutic strategies and prognosis over the course of last two decades. At our center, management follows established evidence based guidelines which are updated as soon as new evidence becomes available. The center is also a tertiary referral center for relapsed and refractory renal cancers treatment. KFSH&RC is the largest transplant center in the Middle East. We are members of Southwest Oncology Group (SWOG) and Radiation Therapy Oncology Group (RTOG) in an effort to provide cutting edge treatment to our patients and to promote research and training in this vital area. REFERENCES:
1. Saudi Cancer Registry Annual Report, 2014. 2. KFSH&RC, Tumor Registry Annual Report, 2013. 3. Globocan 2012: http://globocan.iarc.fr/, Accessed Dec 21, 2017. 4. American Cancer Society (ACS). Cancer Facts & Figures 2017. Atlanta, GA, USA:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
5. ACS Global Cancer Facts and Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf
6. Alkhateeb SS, Alkhateeb JM, Alrashidi EA. Increasing trends in kidney cancer over the last 2 decades in Saudi Arabia. Saudi Med J. 36(6):698-703, 2015.
7. Ghosn M, Jaloudi M, Larbaoui B, et al. Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East. Pan Arab Journal of Oncology. 8(2):38-43, 2015.
8. Lipworth L, Tarone RE, Lund L, et al: Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epidemiol 1:33-43, 2009.
9. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7:245-257, 2010.
10. Abomelha MS. Trends of genitourinary cancer among Saudis. Arab J Urol. 9(3): 199-202, 2011. 11. Al-Shabanah MO, Jenkin DR, Khafaga YO, et al. Renal cell carcinoma in children. Prognostic
factors. 25(11): 1583-6, 2004. 12. Abomelha MS. Genito-urinary cancer in Saudi Arabia. Saudi Med J. 25(5): 552-6, 2004. 13. Alshaibani K, Raza S, Alfurayh O. The kidney transplant program at King Faisal Specialist Hospital
and Research Center: results of the last 10 years. Transplant Proc. 30(7): 3103-5, 1998.
5151
V. APPENDIX
REQUESTS FOR TUMOR REGISTRY DATA 2014
MOH 2013 Statistics Ministry of Health
All patient population diagnosed as Desmoid Tumor Dr. A. Suhaibani
or Fibromatosis in KFSH&RC from 2001-2014
Malignant thymoma cases at KFSH&RC from 1978-2014 Dr. E. Devol
Adult Ewing Sarcoma cases in KFSH&RC from 1997-2014 Dr. A. Memon
Giant cell tumor cases from 2002-2014 at KFSH&RC Dr. M. Elshenawy
Acute promyelocytic leukemia from 1975-2014 at KFSH&RC Dr. A. Hanbali
Hodgkin’s lymphoma cases at KFSH&RC Dr. M. Rauf
Lymphoma cases from 1975-2014 at KFSH&RC Dr. I. Maghfoor
Multiple myeloma cases from 1984-2014 at KFSH&RC Dr. F. Alsharif
Cardiac sarcoma KFSH&RC patients from 1990-2014 Dr. N. Jastaniyah
DLBCL/NHL cases with gastric involvement Dr. S. Akhtar
Giant cell tumor patients on chemotherapy from 2003-2014 Dr. M. Elshenawy
Metastatic colorectal carcinoma treatment data from 2005-2014 Dr. A. Alzahrani
Metaplastic breast carcinoma cases from 2000-2014 Dr. M. Elshenawy
5252
Colorectal Cancer Cases with metastectomy 2005-2013 Dr. A. AlZahrani
All lymphoma patient population NHL,HL, NOS with Dr. S. Akhtar
any type of second cancers 1975-2013
List of All NHL, HL seen and their diagnosis 1975-2013 Dr. S. Akhtar
Epithelial Ovarian Cancer (Age < or= 50) from 2008-2013 Dr. H. AlHusaini
All Metastatic Nasopharyngeal Cancers from 1975-2013 Dr. A. Memon
Micropapillary Thyroid Cancers from 2002-2013 Dr. A. AlZahrani
Pancreatic Adenocarcinoma from 2005-2014 Dr. M. AlSebayel
Follicular Lymphoma with or without extranodal involvement Dr. S. Akhtar
and < 30 years of age (1975-2013)
5353
VI. GLOSSARY OF TERMS Accessioned: Cases are entered into the Tumor Registry by the year in which they were first seen at KFSH&RC for each primary cancer. Age of Patient: Recorded in completed years at the time of diagnosis. Analytic Cases: Cases which were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC. Non-Analytic Cases: Cases diagnosed elsewhere and received all of their first course of treatment elsewhere. Case: A diagnosis or finished abstract. A patient who has more than one primary is reported as multiple cases. Crude Relative Frequency: The proportion of a given cancer in relation to all cases in a clinical or pathological series. First Course of Treatment: The initial tumor-directed treatment or series of treatments, usually initiated within four months after diagnosis. Stage of Disease: Extent of disease process determined at first course of treatment. SEER (Surveillance, Epidemiology and End Results) Summary Staging:
In Situ: Tumor meets all microscopic criteria for malignancy except invasion.
Local: Tumor is confined to organ of origin.
Regional: Tumor has spread by direct extension to immediately adjacent organs and/or lymph nodes and appears to have spread no further.
Distant: Tumor has spread beyond immediately adjacent organs or tissues by direct extension and/or has either developed secondary or metastatic tumors, metastasized to distant lymph nodes or has been determined to be systemic in origin.
AJCC (American Joint Committee on Cancer) TNM Staging: A classification scheme based on the premise that cancers of similar histology or site or origin share similar patterns of growth and extension. T+N+M = Stage T: Extent of primary tumor N: Extent of regional lymph node involvement M: Distant Metastasis
Clinical Stage: Classification based on the evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant findings. Pathologic Stage: Classification based on the evidence acquired before treatment, supplemented or modified by the additional evidence acquired from surgery and from pathologic examination of the resected specimen.
5452
5553
56